



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2898958 A1 2014/07/31

(21) **2 898 958**

**(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) A1

(86) **Date de dépôt PCT/PCT Filing Date:** 2014/01/23
(87) **Date publication PCT/PCT Publication Date:** 2014/07/31
(85) **Entrée phase nationale/National Entry:** 2015/07/22
(86) **N° demande PCT/PCT Application No.:** IB 2014/058500
(87) **N° publication PCT/PCT Publication No.:** 2014/115103
(30) **Priorité/Priority:** 2013/01/24 (EP13305082.3)

(51) **Cl.Int./Int.Cl. C12N 15/113 (2010.01),
A61K 31/712 (2006.01)**

(71) Demandeurs/Applicants:
PIERRE FABRE MEDICAMENT S.A.S., FR;
FUNDACIO HOSPITAL UNIVERSITARI VALL
D'HEBRON - INSTITUT DE RECERCA, ES

(72) Inventeurs/Inventors:
ASIN, MIGUEL-ANGEL, ES;
FERRET, EULALIA, ES;
PEREZ, AMADEO, ES;
GOTARDA, NEUS BELLERA, ES;
RODRIGUEZ SINOVAS, ANTONIO, ES;
...

(54) **Titre : COMPOSITION COMPRENANT UN ANTAGOMIR ENCAPSULE**
(54) **Title: COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR**

(57) Abrégé/Abstract:

The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemia.

(72) **Inventeurs(suite)/Inventors(continued):** VERT, IGNASI BARBA, ES; GARCIA-DORADO GARCIA, ANTONIO DAVID, ES

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number

WO 2014/115103 A1

(43) International Publication Date
31 July 2014 (31.07.2014)

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/712* (2006.01)

(21) International Application Number:
PCT/IB2014/058500

(22) International Filing Date:
23 January 2014 (23.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13305082.3 24 January 2013 (24.01.2013) EP

(71) Applicants: **PIERRE FABRE MEDICAMENT S.A.S.** [FR/FR]; 45 Place Abel Gance, F-92654 Boulogne Cedex (FR). **FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA** [ES/ES]; 119-129 Passeig Vall d'Hebron, E-08035 Barcelona (ES).

(72) Inventors: **ASIN, Miguel-Angel**; Carretera Barcelona 103-107 2º-2a, E-08290 Cerdanyola Del Valles (ES). **FERRET, Eulalia**; c/Flaquer, 16, E-08820 El Prat De Llobregat (ES). **PEREZ, Amadeo**; C/Pobla de Lillet,16, 4º- 4a, E-08028 Barcelona (ES). **GOTARDA, Neus Bellera**; DNI 43445420F, Av Meridiana 326 11è4a, E-08027 Barcelona (ES). **RODRIGUEZ SINOVAS, Antonio**; DNI 36984974P, C/Floridablanca 55-57 4º3a, E-08015 Barcelona (ES). **VERT, Ignasi Barba**; DNI 45461118P, Pg de les lletres 12 1º 4a, E-08225 Terrassa (ES). **GARCIA-DORADO GARCIA, Antonio David**; DNI 1397791N, Av Vallvidrera 18, 1er, E-08018 Barcelona (ES).

(74) Agent: **JUPIN, Claude**; Cabinet Nony, 3 rue de Penthièvre, F-75008 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2014/115103 A1

(54) Title: COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR

(57) Abstract: The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemia.

“Composition comprising an encapsulated antagonir”

Field of the invention

The present invention relates to the field of pharmaceutical formulations aimed at 5 preventing or treating cardiac disorders, including cardiac ischemic disorders.

Background of the invention

Acute myocardial infarction (AMI), also referred as myocardial infarction and 10 commonly known as a heart attack, represents a major health risk in most industrialized nations throughout the world and remains a leading cause of morbidity and mortality 15 worldwide.

Generally, AMI is caused by a sudden and sustained lack of blood flow to the heart tissue, which is usually the result of a narrowing or occlusion of a coronary artery. Without 15 adequate blood supply, the tissue becomes ischemic, leading to the death of cardiomyocytes (heart muscle cells) and vascular structures.

There have been many advances in the treatment of AMI in recent decades, primarily in relation to coronary reperfusion in conjunction with pharmacological therapy. Reperfusion therapy has succeeded in changing the natural progression of AMI by 20 reducing the infarcted area and improving short-term and long-term morbidity and mortality. However, there are substantial limitations to the use of the two reperfusion strategies currently available: fibrinolysis results in a low degree of coronary permeability and primary angioplasty cannot be applied frequently during the initial hours of evolution 25 of the AMI. Furthermore, in some catheterized patients, the “no reflow” phenomenon or absence of microvascular reperfusion despite normal epicardial flow occurs, which results in adverse functional outcomes. This means that reperfusion therapy has not prevented the occurrence of deleterious remodelling of the myocardium, a complex intrinsic reparative process of collagen scar formation resulting in ventricular dilatation, contractile 30 dysfunction and subsequent heart failure. Its occurrence, in approximately 30% of AMIs, has been mainly associated to higher infarction size, microvascular obstruction and unfavourable repair reactions still poorly understood.

Since reparative fibrosis and functional recovery of ischemic tissues is dependent on establishing networks that supply oxygenated blood, efforts have been made to improve vascular bed by inducing neoangiogenesis in the healing area for achieving direct conversion of injured areas to functional tissue *in situ*.

Therapeutic induction of angiogenesis could attenuate the occurrence of this phenomenon. Notwithstanding, the results of several years of clinical trials with intravenous proangiogenic factors have been unsatisfactory. Without being linked by a theory, it is considered that one of the reasons accounting for this failure may be that the 5 intravenous route may not be able to reach and maintain an effective concentration of drug in the target tissue to promote and maintain a functional vascular network under severely compromised heart conditions.

In order to address this problem and prevent post-AMI cardiac insufficiency, research on the possibility of regenerating cardiac muscle and vessels was started within 10 the last decade. Initial studies administrating pluripotent progenitor cells and infusing vascular growth factors showed promising results but the translation to the clinical setting showed inability of these therapies to regenerate neovasculature in an adequate manner for enabling destroyed cardiac muscle to recover.

At this day, the angiogenesis and repopulation of injured heart with cell therapy as 15 well as specific drugs and resynchronization therapy can slow down the progression of this phenomenon but prevention of its occurrence remains a doubting challenge for cardiac medicine. Therefore, novel treatment strategies preventing adverse left ventricular remodelling are required.

20 **Summary of the invention**

The present invention relates to the treatment of cardiac, preferably ischemic disorders by administering a composition that reverses or prevents ventricular remodelling by modulating the activity or expression of microRNAs. More particularly, the invention provides a composition comprising an inhibitor of a microRNA involved in angiogenesis, 25 said inhibitor being preferably incorporated into a new delivery vehicle capable of releasing the inhibitor locally to the ischemic target tissue. In addition, the invention provides a method of reversing or preventing ventricular remodelling and kits useful for said method.

This invention relates to a composition comprising an effective amount of at least 30 one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres.

In some embodiments of the composition described above, the said miRNA is selected in the family comprising miR-92 (including miR-92a-1, miR-92a-2 and miR-92b),

miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b).

5 In some embodiments of the composition described above, the said inhibitor of a miRNA is an oligonucleotide of 8-49 nucleotides in length having a sequence targeted to the said miRNA, or a precursor thereof. In certain embodiments, the said oligonucleotide is an antisense oligonucleotide that is at least partially complementary to the sequence of the target miRNA, or a precursor thereof. The said antisense oligonucleotide may be selected 10 from the group consisting of a ribonucleotide, a deoxyribonucleotide, a small RNA, an antagomir, a LNA, a CDNA, a PNA, a morpholino oligonucleotide or a combination thereof.

In some embodiments of the composition described above, the said inhibitor of a miRNA consists of an antagomir, and preferably consists of an antagomir comprising a 15 nucleotide sequence comprising at least 16 contiguous nucleotides complementary to the nucleotides of a sequence selected from the group consisting of SEQ ID No. 1 to 58 described herein.

In some embodiments of the composition described above, the said inhibitor of a miRNA consists of an antagomir comprising the sequence SEQ ID No. 59 or 60 and 20 modifications excluding base substitutions thereof, and fragments consisting of subsequences of SEQ ID NO: 59 or 60 of at least 8 contiguous nucleotides thereof.

In some embodiments of the composition described above, the said microspheres are presenting a diameter which does not exceed 25 μm , which encompasses microspheres having a diameter comprised between 5 and 20 μm , preferentially between 5 and 15 μm .

25 In some embodiments of the composition described above, the said microspheres are made of a polymer consisting of poly-d,l-lactide (PLA), the said polymer being optionally blended with one or more other polymers.

This invention also relates to a method for reversing or preventing ventricular remodelling in a subject in need thereof comprising administering to said subject an 30 effective amount of a composition as described above.

This invention also pertains to a population of biodegradable and biocompatible microspheres for use in the treatment or prevention of myocardial infarction, wherein said microspheres:

- have an average diameter comprised between 5 and 20 μm , preferentially between 5 and 15 μm ;
- are made of poly-d,l-lactide-co-glycolide (PLGA) ; poly-d,l-lactide (PLA) or a blend thereof;
- 5 - are incorporating from 1% to 15% w/w of a therapeutic agent capable of preventing ventricular remodelling,

wherein said therapeutic agent consists of an inhibitor of a miRNA selected from the group consisting of miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, 10 miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b) and more preferentially miR-92a, or a precursor thereof.

15 Description of the figures

Figure 1 illustrates the morphology of antagonir-92a – PLGA microspheres determined by scanning electron microscopy;

Figure 2 illustrates the size distribution of antagonir-92a – PLGA microspheres determined by laser light scattering;

20 **Figure 3** illustrates effects in hemodynamic and left ventricular contractility by repeated injections of microspheres until 120mg;

Figure 4 illustrates effects in hemodynamic and left ventricular contractility by repeated injections of microspheres until 240mg;

25 **Figure 5** illustrates the protocol of the study of the molecular effect of a single intracoronary injection of microspheres according to the invention;

Figure 6 illustrates the miR-92a inhibition specificity by the microspheres according to the invention;

30 **Figure 7** illustrates the encapsulated antagonir-92a induces angiogenesis in infarcted tissue. Vascular density in infarcted zone, calculated dividing the total number of vessels by the total infarcted area. N=20. * P< 0.01;

Figure 8: Indirect Measurement. Basal and minimal microvascular resistance index measured one month after AMI, in the infarct related artery of minipigs treated with encapsulated antagonir-92a, placebo or saline. (a) Basal microvascular resistance index (MRI) was calculated by multiplying pressure (mmHg) assessed with a pressure wire in

positioned in the apical LAD (Pd) and coronary flow (ml/min) quantified by a sensor positioned in the distal segment of LAD. Minimal microvascular resistance index (MRI_{hyp}) was calculated with the same parameters measured in maximal hyperemia achieved with intravenous infusion of 140 micro/Kg/min of adenosine administered through the femoral vein 12F sheath. n= 12 * p<0.01 ** p=0.05 (b) Correlation between the total number of vessels in the necrotic area and MRI. R² 0.41, p=0.02, n=12. (c) Correlation between the total number of vessels in the necrotic area and minimal MRI. R² 0.27, p=0.08, n=12;

Figure 9: Direct Measurement. Baseline and true microcirculatory resistance measured one month after AMI in the infarct-related artery of minipigs treated and non-treated with encapsulated antagonmir-92a. (a) Baseline microcirculatory resistance (baseline MR) was calculated by dividing pressure (mmHg) assessed with a pressure wire positioned in the apical LAD (Pd) by coronary flow (ml/min) quantified by a sensor positioned in the distal segment of LAD. The baseline MR was significantly lower in the treated group compared with controls (7.47±1.33 vs 19.62±2.98, p=0.005). n=13. True microcirculatory resistance (TMR (hyp)) was calculated measuring the same parameters during maximal hyperemia achieved with intravenous infusion of 140 micro/kg/min of adenosine administered through the femoral vein 12F sheath. Significantly lower TMR (hyp) was observed in the treated group compared to controls (5.0±1.15 vs 14.49±2.4, p= 0.006). n= 13 (b) Correlation between the vascular density in all necrotic area and baseline MR. R²=0.35, P=0.033, n=13. (c) Correlation between the vascular density in all necrotic area and TMR (hyp). R²=0.31, P=0.047. n=13.

Figure 10: One month after AMI, the presence of septoapical diskynesia was evaluated by an echocardiographer blind to the allocated treatment. The percentage of animals with septoapicaldiskynesia in treated and non-treated animals is shown (83.3% vs 25 16.7%, p=0.03). n=20.

Figure 11: evaluation of the effects of encapsulated antagonmir 92a and non encapsulated antagonmir 92a on the expression of miR92a *in vitro*.

Figure 12: Effect of encapsulated antagonmirs 17 and 20a on their respective miRNAs

30

Detailed Description of the invention

Some definitions are given hereunder that are relevant as regards the description of the whole embodiments that are encompassed by the present invention.

MicroRNAs (miRs) are small, noncoding RNAs that are emerging as crucial regulators of biological processes.

"MicroRNA", "miRNA" or "miR" means a non coding RNA of about 18 to about 25 nucleotides in length. These miRs could originate from multiple origins including: an 5 individual gene encoding for a miRNA, from introns of protein coding gene, or from polycistronic transcript that often encode multiple, closely related microRNAs.

Current knowledge shows that miRNAs are transcribed by RNA polymerase II (pol II) or RNA polymerase III (pol III) and arise from initial transcripts, termed primary miRNA transcripts (pri-miRNAs), that are generally several thousand bases long. Pri- 10 miRNAs are processed in the nucleus by the RNase Drosha into about 70 to 100-nucleotide hairpin-shaped precursors (pre-miRNAs). Following transport to the cytoplasm, the hairpin pre-miRNA is further processed by Dicer to produce a double-stranded microRNA; one of the strands, the so called mature microRNA, (sometimes both strands can be used) is then incorporated into the RNA-induced silencing complex (RISC), where it associates with its 15 target mRNAs by base-pair complementarity. In the relatively rare cases in which a miRNA base pairs perfectly with a messenger RNA (mRNA) target, it promotes mRNA degradation. More commonly, microRNAs form imperfect heteroduplexes with target mRNAs, affecting either mRNA stability or inhibiting mRNA translation.

"Stem-loop sequence" means a RNA having a hairpin structure and containing a 20 mature microRNA sequence. Pre-miRNA sequences and stem-loop sequences may overlap. Examples of stem-loop sequences are found in the microRNA database known as miRBase.

"microRNA precursor" means a transcript that originates from a genomic DNA and that comprises a non-coding, structured RNA comprising one or more microRNA 25 sequences. For example, in certain embodiments a microRNA precursor is a pre-miRNA. In certain embodiments, a microRNA precursor is a pri-miRNA.

The following specification will follow the standard nomenclature system with the uncapitalized "mir-X" refers to the pre-miRNA, while a capitalized "miR-X" refers to the mature form. When two mature microRNAs originate from opposite arms of the same pre- 30 miRNA, they are denoted with a -3p or -5p suffix. When relative expression levels are known, an asterisk following the name indicates a microRNA expressed at low levels relative to the microRNA in the opposite arm of a hairpin.

In the following specification, unless otherwise specified, the use of the expression miR-X refers to the mature miRNA including both forms -3p and -5p, if any.

For the avoidance of doubt, in the present specification, the expressions microRNA, miRNA and miR designate the same product.

In the context of the present invention, it is an objective to modulate angiogenesis or angiogenic processes with, as a consequence, a particular focus on microRNA involved in angiogenesis. It is thus an objective of the invention to modulate at least one microRNA belonging to a family of microRNAs involved in the modulation of the angiogenesis.

By the expression “microRNA family”, it is intended a group of microRNAs with a related function consisting of the modulation of angiogenesis or angiogenic processes. 10 More particularly, without limitation, said microRNAs are selected in the group consisting of microRNAs presenting an antiangiogenic activity.

More particularly, without limitation, such microRNA are selected in the group consisting of miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b 15 and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), or precursors thereof. As it will be obvious for the person skilled in the art, any miRNA having modulating, preferentially antagonist, properties on angiogenesis should be considered as part of this microRNA family.

20 For the avoidance of doubt, the expression microRNA in the following specification, unless otherwise indicated, shall refer to the mature or processed RNA after it has been cleaved from its precursor. For the non mature forms, the expression “precursors” or “microRNA precursors” will be used.

The following table 1 regroups the different sequences of the microRNA precursors 25 encompassed by the present specification.

SEQ ID NO:	Name	Sequence
1	mir-92a-1	CUUUCUACACAGGUUGGAUCGGUUGCAAUGCUGUUUCUGUAUGGUAUUG CACUUGUCCCGGCCUGUUGAGUUUUG
2	mir-92a-2	UCAUCCCUGGGUGGGAUUUGUUGCAUUACUUGUGUUCUAUAUAAGUAUUG CACUUGUCCCGGCCUGUGGAAGA
3	mir-92b	CGGGCCCCGGCGGGCGGGAGGGACGGGACGCCGGUGCAGUGUUUUUCC CCGCCAAUUAUUGCACUCGUCCCCGGCCUCCGGCCCCCGGCC
4	mir-17	GUCAGAAUAAUGUCAAAGUGCUUACAGUGCAGGUAGUGUAUGUGCAUCUAC UGCAGUGAAGGCACUUGUAGCAUUAUGGUGAC
5	mir-503	UGCCCUAGCAGCGGAACAGUUCUGCAGUGAGCGAUCGGUGCUCUGGGUAU UGUUUCCGCUGCCAGGGUA
6	mir-16-1	GUCAGCAGUGCCUUAGCAGCACGUAAAUAUUGCGUUAAGAUUCUAAAAUUA UCUCCAGUAUUAACUGUGCUGCUGAAGUAAGGUUGAC
7	mir-16-2	GUUCCACUCUAGCAGCACGUAAAUAUUGCGUAGUGAAUUAUUAUUAACA CCAAUAAUACUGUGCUGCUUAGUGUGAC
8	mir-374a	UACAUCGGCAUUAAAACAACCUGAUAGUGUUUAGCACUUACAGAUU GUAUUGUAAUUGUCUGUGUA
9	mir-374b	ACUCGGAUGGAUAAAACAACCUGCUAGUGUCCUAGCACUUAGCAGGUUG UAUUAUCAUUGUCCGUGUCU
10	mir-374c	ACACGGACAAUGAUAAAACAACCUGCUAGUGCUAGGACACUUAGCAGGUUG UAUUAUAAUCCAUCGGAGU
11	mir-24-1	CUCCGGUGCCUACUGAGCUGAUACAGUUCUCAUUUACACACUGGCUCAGU UCAGCAGGAACAGGAG
12	mir-24-2	CUCUGCCUCCCGUGCCUACUGAGCUGAAACACAGUUGGUUGUGUACACUGG CUCAGUUCAGCAGGAACAGGG
13	mir-483	GAGGGGAAGACGGAGGAAAGAAGGGAGUGGUUCCAUCACGCCUCCUCACU CCUCUCCUCCGUCUUCUCCUCUC
14	mir-34a	GGCCAGCUGUGAGGUUCUUGGCAGUGCUUAGCUGGUUGUUGUGAGCAA UAGUAAGGAAGCAAUCAGCAAGUAUACUGCCCAGAAGUGCUGCAGGUUGUG GGGCC
15	mir-34b	GUGCUCGGUUUGUAGGCAGUGUCAUAGCUGAUUGUACUGUGGGUGGUUACAA UCACUAACUCCACUGCCAUCAAAACAAGGCAC
16	mir-34c	AGUCUAGUUACUAGGCAGUGUAGGUAGCUGAUUGCUCUAAAGUACCAAUCACU AACACACGGCCAGGUAAAAAGAUU
17	mir-20a	GUAGCACUAAAGUGCUUUAUGUGCAGGUAGUGUUUAGUUAUCUGCAUUA UGAGCACUUAAGUACUGC
18	mir-20b	AGUACCAAAGUGCUCAUAGUGCAGGUAGUUUUGCAUGACUCUACUGUAGUA UGGGCACUUCAGUACU
19	mir-15a	CCUUGGAGUAAGUAGCAGCACAUAAUGGUUGUGGAUUUUGAAAAGGUGCA GCCCAUUAUGUGCUGCCUCAAAACAGG
20	mir-15b	UUGAGGCCUUAAAGUACUGUAGCAGCACAUCAUGGUUACAUGCUACAGUCA AGAUGCGAAUCAUUAUUGCUGCUCUAGAAUUAAGGAAUUCAU

Table 1

5

The following table 2 indicates, for each microRNA, the sequences of the microRNA and the corresponding residues into the corresponding precursor sequences (see table 1).

SEQ ID NO:	Name	Sequence	Residues from precursor
21	miR-92a-3p	uauugcacuugucccgccugu	48-69
22	miR-92a-1-5p	aggugggauccgguugcaaugcu	11-33
23	miR-92a-2-5p	ggguggggauuuguugcauuac	9-30
24	miR-92b-3p	uauugcacucgucccgccucc	61-82
25	miR-92b-5p	aggcacgggacgcggugcagug	20-41
26	miR-17-3p	acugcagugaaggcacuuguag	51-72
27	miR-17-5p	caaagugcuaacagugcagguag	14-36
28	miR-503-3p	gggguaauuguuuccgcugccagg	46-68
29	miR-503-5p	uagcagcggaaacaguucugcag	6-28
30	miR-16-1-3p	ccaguauuaacugugcugcuga	56-77
31	miR-16-2-3p	ccaaauuuacugugcugcuaua	53-74
32	miR-16-5p	uagcagcacguaaauauuggcg	14-35 (for miR-16-1) or 10-31 (for miR-16-2)
33	miR-374a-3p	cuuaucagauuguaauuguaauu	42-63
34	miR-374a-5p	uuauaaauacaaccugauaagug	12-33
35	miR-374b-3p	cuuagcagguuguaauaucauu	41-62
36	miR-374-5p	auauaaauacaaccugcuaagug	11-32
37	miR-374c-3p	cacuuagcagguuguaauauau	39-60
38	miR-374c-5p	auaaauacaaccugcuaagugcu	13-34
39	miR-24-1-3p	uggcucaguucagcaggaacag	44-65
40	miR-24-1-5p	ugccuacugagcugauaucagu	7-28
41	miR-24-2-3p	uggcucaguucagcaggaacag	50-71
42	miR-24-2-5p	ugccuacugagcugaaacacag	13-34
43	miR-483-3p	ucacuccucuccuccgucuu	48-68
44	miR-483-5p	aagacgggaggaaagaaggag	8-29
45	miR-34a-3p	caaucagcaaguauacugccu	64-85
46	miR-34a-5p	uggcagugucuuagcugguugu	22-43
47	miR-34b-3p	caaucacuaacuccacugccau	50-71
48	miR-34b-5p	uaggcagugucauuagcugauug	13-35

49	miR-34c-3p	aaucacuaaccacacggccagg	46-67
50	miR-34c-5p	aggcaguguaguuagcugauugc	13-35
51	miR-20a-3p	acugcauuauugagcacuuuaag	44-65
52	miR-20a-5p	uaaagugcuuauagugcagguag	8-30
53	miR-20b-3p	acuguaguaugggcacuuccag	44-65
54	miR-20b-5p	caaagugcucauagugcagguag	6-28
55	miR-15a-3p	caggccauauugugcugccuca	51-72
56	miR-15a-5p	uagcagcacauaaugguuugug	14-35
57	miR-15b-3p	cgaaucauuauugcugcucua	58-79
58	miR-15b-5p	uagcagcacaucaugguuuaca	20-41

Table 2

Unless otherwise indicated, precursor and microRNA sequences referred to in the application are human sequences. Nevertheless, in some cases, microRNA human sequences are homologous to microRNA sequences from other species.

As an example, it can be mentioned here that the human miR-92a is homologous to miRs from other species. More particularly, the human miR-92a is homologous to miRs from dme (*Drosophila melanogaster*), mmu (*Mus musculus*), rno (*Rattus norvegicus*), dps (*Drosophila pseudoobscura*), aga (*Anopheles gambiae*), dre (*Danio rerio*), mml (*Macaca mulatta*), xtr (*Xenopus tropicalis*), ame (*Apis mellifera*), odi (*Oikopleura dioica*), cin (*Ciona intestinalis*), csa (*Ciona savignyi*), cfa (*Canis familiaris*) and pig or ssc (*Sus scrofa*).

Based on its general knowledge, the person skilled in the art will find easily the homology between other human microRNA sequences and microRNA sequences from other species.

Nucleotide sequences of mature microRNAs and their corresponding stem-loop sequences described herein are the sequences found in miRBase, an online searchable database of microRNA sequences and annotation. Entries in the miRBase Sequence database represent a predicted hairpin portion of a microRNA transcript (the stem-loop), with information on the location and sequence of the mature microRNA sequence. The microRNA stem-loop sequences in the database are not strictly precursor miRNAs (pre-

miRNAs), and may in some instances include the pre-miRNA and some flanking sequence from the presumed primary transcript.

It is thus an objective of the present invention to provide compositions for the treatment or prevention of ventricular remodelling after AMI comprising an inhibitor of 5 microRNA, or a combination of inhibitors of several microRNAs, involved in different reactions governing the physiology of angiogenesis, or precursors thereof.

However, in most of the published studies, the intravenous route is used for administering microRNA inhibitors in animals. The manipulation of microRNA involved in the regulation of vascular genes expression represents a novel therapeutic target in 10 ischaemic disease. Within the biomedical sector, there has been an exponential increase in research on the administration of RNA modulators especially designed to inhibit a particular RNA sequence.

Dimmeler et al have shown improvement in contractility and recovery of left ventricular function after miR-92a inhibition by specific microRNA inhibitor administered 15 systemically. Since the polycistronic microRNA 17-92a cluster has been linked to tumorigenesis and because of microRNAs cellular type ubiquity, intravenous administration in repetitive injections of miR or anti-miRs raises concerns about safety.

Owing to the fact that microRNAs control complex processes and are present in various cellular pathways, it is highly probable that they also trigger significant side 20 effects. An issue, among other ones, at present is that treatments with miRNA inhibitors are not selective.

In addition, given the ubiquitousness and low organ specificity of these molecules, systemic administration could lead to exercise regulatory functions in tissues where these 25 miRNAs have different cell-specific functions or where are not normally expressed. This erroneous regulation would likely lead to triggering side effects. Among the potential risks, tumorigenesis associated with microRNA manipulation remains one of the primary concerns when applying this therapy to human pathology. Moreover, in order to obtain an adequate sustained concentration in the target cells, microRNA inhibitors must be repeatedly injected at very high doses. Although experimentation on small animals in 30 controlled conditions carries minor limitations, the transposition to human beings presupposes obstacles to biosafety as well as logistical and economic hindrances.

In order to solve these problems and enable this new therapeutic approach to be transferred to patients, it is there considered to generate a release vehicle for transporting microRNA inhibitors and releasing them directly onto the target organ. An appropriate

vehicle would direct the microRNA inhibitor straight to the diseased tissue thereby enabling a reduction in dosage, so as to avoid the administration of repeated injections and minimise potentially undesirable biological effects on other organs.

The objective is therefore to improve selectivity in order to avoid the side effects of 5 these treatments by means of releasing the microRNA inhibitors only in target tissue. This issue is solved, according to the invention, by microencapsulating the microRNA inhibitors into biodegradable and biocompatible microspheres.

It is thus an objective of the present invention to provide compositions for the treatment or prevention of ventricular remodelling after AMI comprising at least one 10 microencapsulated inhibitor of a microRNA belonging to the microRNA family related to the modulation of angiogenesis, which microRNA family comprises, without limitation, the miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, 15 miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), or a precursor thereof.

By microencapsulating microRNA inhibitors in microspheres, intra-arterial administration after transluminal angioplasty is facilitated, so that the microspheres are delivered and retained only in the microvessels, also referred to as capillaries, of the 20 damaged area; in this way the encapsulated microRNA inhibitors can be released locally.

Intracoronary injection through the culprit artery of AMI enables retention of the microspheres in the coronary microcirculation and sustained release of the microRNA inhibitors directly in the target ischemic tissue. The microRNA inhibitors induce neoangiogenesis which enhances functional recovery of the contractility of the damaged 25 tissue as well as favourable post-infarction remodelling.

Unexpectedly, it is shown herein that, when it is microencapsulated into appropriate microspheres, a microRNA inhibitor and especially an inhibitor of a microRNA belonging to the microRNA family related to the modulation of angiogenesis, the said microRNA is successfully released to the damaged area of the myocardium so as 30 to block the biological activity of the target microRNA. As shown in the examples herein, the administration, by selective intracoronary route, of a given microRNA inhibitor, i.e. as non limitative example an inhibitor of miR-92a, that is microencapsulated into polymeric biodegradable and biocompatible microspheres to individuals having undergone a myocardial infarction leads to myocardial functional recovery.

Therefore, microspheres retained in microcirculation allow sustained release of the microRNA inhibitor directly in the target ischemic tissue. The sustained effect of microRNA inhibitors (also known as down-regulation) of targeted microRNA resulted in a significant vessel growth and suppression of adverse remodeling in the healing area one 5 month after injury.

As shown in the examples herein, it has been demonstrated that the occurrence of adverse ventricular remodelling can be prevented by inducing vasculogenesis through local and sustained inhibition of a microRNA belonging to the microRNA family related to the modulation of angiogenesis by encapsulated appropriate microRNA inhibitor administered 10 in the infarcted related artery. This represents a new delivery method that will facilitate the next safety translation of gene modulation therapy to patients that suffer an acute myocardial infarction.

These results clearly show that a composition comprising an inhibitor of microRNA belonging to the microRNA family related to the modulation of angiogenesis, 15 such as miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), or a precursor thereof, as disclosed herein allows an 20 effective local release of the said inhibitor in therapeutically effective amounts and at a therapeutically effective release rate.

In a first aspect, the invention relates to a composition comprising an effective amount of at least one inhibitor of a microRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric 25 biodegradable and biocompatible microspheres.

In another aspect, the invention relates to a composition comprising an effective amount of at least one inhibitor of a microRNA selected in the family comprising miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres.

In still another aspect of the invention, the invention relates to a composition comprising an effective amount of at least one inhibitor of miR-92a, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres.

5 By the expression "microspheres", it must be understood spherical particles sized from 1 μ m to few hundred μ m. The expression "microparticles" includes both "microspheres" and "microcapsules". In the present specification, the expression "microspheres" is used but it must be understood that, when the substitution with a "microcapsule" is possible and of interest according to the man skilled in the art, the use of 10 "microspheres" and "microcapsules" is equivalent.

By the expression "encapsulated" or "microencapsulated", it must be understood enclosed or embedded in particles for protection or for modified release.

In other words, the invention relates to a pharmaceutical composition comprising an effective amount of at least one inhibitor of a microRNA involved in angiogenesis, said 15 inhibitor of a microRNA being preferably selected from the group comprising, or alternatively consisting of miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), 20 miR-15 (including miR-15a and miR-15b), or a precursor thereof, microencapsulated in biodegradable and biocompatible microspheres.

In other words, the invention relates to a pharmaceutical composition comprising an effective amount of at least one inhibitor of miR-92a, or a precursor thereof, microencapsulated in biodegradable and biocompatible microspheres.

25 "Pharmaceutical composition" means a mixture of substances suitable for administering to an individual that includes a pharmaceutical agent. For example, a pharmaceutical composition may comprise a miRNA inhibitor and a sterile aqueous solution.

In an embodiment of the composition of the invention, the said miRNA involved in 30 angiogenesis consists of a mature miRNA.

In an embodiment of the composition of the invention, the said microRNA consists of the mature:

- a) miR-92a comprising a sequence selected from the group consisting of SEQ ID No. 21, 22 or 23 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 21, 22 or 23;
- b) miR-92b comprising a sequence selected from the group consisting of SEQ ID No. 24 or 25 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 24 or 25;
- c) miR-17 comprising a sequence selected from the group consisting of SEQ ID No. 26 or 27 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 26 or 27;
- d) miR-503 comprising a sequence selected from the group consisting of SEQ ID No. 28 or 29 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 28 or 29;
- e) miR-16 comprising a sequence selected from the group consisting of SEQ ID No. 30, 31 or 32 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 30, 31 or 32;
- f) miR-374 comprising a sequence selected from the group consisting of SEQ ID No. 33, 34, 35, 36, 37 or 38 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 33, 34, 35, 36, 37 or 38;
- g) miR-24 comprising a sequence selected from the group consisting of SEQ ID No. 39, 40, 41 or 42 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 39, 40, 41 or 42;
- h) miR-483 comprising a sequence selected from the group consisting of SEQ ID No. 43 or 44 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 43 or 44;
- i) miR-34 comprising a sequence selected from the group consisting of SEQ ID No. 45, 46, 47, 48, 49 or 50 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 45, 46, 47, 48, 49 or 50;
- j) miR-20 comprising a sequence selected from the group consisting of SEQ ID No. 51, 52, 53 or 54 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 51, 52, 53 or 54; and
- k) miR-15 comprising a sequence selected from the group consisting of SEQ ID No. 55, 56, 57 or 58 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 55, 56, 57 or 58.

In another embodiment of the composition of the invention, the said miR-92a consists of the mature miR-92a comprising the sequence SEQ ID No. 21 or a sequence having at least 90%, preferably 95%, nucleotide identity with SEQ ID NO 21.

5 In another embodiment of the composition of the invention, the said miR-92a consists of the mature miR-92a comprising the sequence SEQ ID No. 22 or a sequence having at least 90%, preferably 95% nucleotide identity with SEQ ID NO 22.

In another embodiment of the composition of the invention, the said miR-92a consists of the mature miR-92a comprising the sequence SEQ ID No. 23 or a sequence having at least 90%, preferably 95%, nucleotide identity with SEQ ID NO 23.

10 In the sense of the present invention, the “percentage identity” between two sequences of nucleic acids means the percentage of identical nucleotides residues between the two sequences to be compared, obtained after optimal alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly along their length. The comparison of two nucleic acid sequences is traditionally 15 carried out by comparing the sequences after having optimally aligned them, said comparison being able to be conducted by segment or by using an “alignment window”. Optimal alignment of the sequences for comparison can be carried out, in addition to comparison by hand, by means of the local homology algorithm of Smith and Waterman 20 (1981), by means of the local homology algorithm of Neddleman and Wunsch (1970, by means of the similarity search method of Pearson and Lipman (1988) or by means of computer software using these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI, or by the comparison software BLAST NR or BLAST P).

25 The percentage identity between two nucleic acid sequences is determined by comparing the two optimally-aligned sequences in which the nucleic acid sequence to compare can have additions or deletions compared to the reference sequence for optimal alignment between the two sequences. Percentage identity is calculated by determining the number of positions at which the nucleotide residue is identical between the two sequences, preferably between the two complete sequences, dividing the number of 30 identical positions by the total number of positions in the alignment window and multiplying the result by 100 to obtain the percentage identity between the two sequences.

As intended herein, nucleotide sequences having at least 90% nucleotide identity with a reference sequence encompass those having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% nucleotide identity with the said reference sequence.

In an embodiment of the composition of the invention, the said miRNA involved in angiogenesis consists of a precursor of microRNA.

In an embodiment of the invention, the said precursor of microRNA involved in the angiogenesis consists of:

- 5 a) mir-92a-1 comprising the sequence SEQ ID No. 1, or a sequence having at least 90% nucleotide identity with SEQ ID No. 1;
- b) mir-92a-2 comprising the sequence SEQ ID No. 2, or a sequence having at least 90% nucleotide identity with SEQ ID No. 2;
- c) mir-92b comprising the sequence SEQ ID No. 3, or a sequence having at least 10 90% nucleotide identity with SEQ ID No. 3;
- d) mir-17 comprising the sequence SEQ ID No. 4 or a sequence having at least 90% nucleotide identity with SEQ ID No. 4;
- e) mir-503 comprising the sequence SEQ ID No. 5 or a sequence having at least 90% nucleotide identity with SEQ ID No. 5;
- 15 f) mir-16-1 comprising the sequence SEQ ID No. 6, or a sequence having at least 90% nucleotide identity with SEQ ID No. 6; and
- g) mir-16-2 comprising the sequence SEQ ID No. 7, or a sequence having at least 90% nucleotide identity with SEQ ID No. 7;
- h) mir-374a comprising the sequence SEQ ID No. 8, or a sequence having at least 20 90% nucleotide identity with SEQ ID No. 8;
- i) mir-374b comprising the sequence SEQ ID No. 9, or a sequence having at least 90% nucleotide identity with SEQ ID No. 9;
- j) mir-374c comprising the sequence SEQ ID No. 10, or a sequence having at least 90% nucleotide identity with SEQ ID No. 10;
- 25 k) mir-24-1 comprising the sequence SEQ ID No. 11, or a sequence having at least 90% nucleotide identity with SEQ ID No. 11;
- l) mir-24-2 comprising the sequence SEQ ID No. 12, or a sequence having at least 90% nucleotide identity with SEQ ID No. 12;
- m) mir-483 comprising the sequence SEQ ID No. 13, or a sequence having at least 30 90% nucleotide identity with SEQ ID No. 13;
- n) mir-34a comprising the sequence SEQ ID No. 14, or a sequence having at least 90% nucleotide identity with SEQ ID No. 14;
- o) mir-34b comprising the sequence SEQ ID No. 15, or a sequence having at least 90% nucleotide identity with SEQ ID No. 15;

- p) mir-34c comprising the sequence SEQ ID No. 16, or a sequence having at least 90% nucleotide identity with SEQ ID No. 16;
- q) mir-20a comprising the sequence SEQ ID No. 17, or a sequence having at least 90% nucleotide identity with SEQ ID No. 17;
- 5 r) mir-20b comprising the sequence SEQ ID No. 18, or a sequence having at least 90% nucleotide identity with SEQ ID No. 18;
- s) mir-15a comprising the sequence SEQ ID No. 19, or a sequence having at least 90% nucleotide identity with SEQ ID No. 19, and
- 10 t) mir-15b comprising the sequence SEQ ID No. 20, or a sequence having at least 90% nucleotide identity with SEQ ID No. 20.

Generally speaking, an inhibitor is a molecule which represses or prevents another molecule from engaging in a reaction.

As used herein, the term "inhibitor of miR-X, or mir-X" refers to any molecule or compound that decreases or reduces the expression and/or activity of miR-X, or mir-X, or 15 at least one precursor. This inhibition should, as a consequence, prevent neo-angiogenesis inhibition, i.e. promote neoangiogenesis so as to prevent the adverse remodelling of cardiac muscle after the infarction.

In one embodiment of the invention, the said inhibitor of a given microRNA involved in the angiogenesis is an oligonucleotide of 8-49 nucleotides in length having a 20 sequence targeted to the said given microRNA, said microRNA being preferably selected from the group comprising miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), 25 miR-15 (including miR-15a and miR-15b), or a precursor thereof.

In another embodiment, the said inhibitor of miR-92a is an oligonucleotide of 8-49 nucleotides in length having a sequence targeted to said miR-92a.

The expression "Targeted to" means having a nucleotide sequence that will allow hybridization to a target nucleic acid to induce a desired effect. In certain embodiments, a 30 desired effect is reduction and/or inhibition of a target nucleic acid.

"Hybridize" means the annealing of complementary nucleic acids that occurs through "nucleotide complementarity", i.e. the ability of two nucleotides to pair non-covalently via hydrogen bonding.

On some embodiments, miRNA inhibitor oligonucleotides are 8 to 49 nucleotides in length.

One having ordinary skill in the art will appreciate that this embodies oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 5 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or 49 nucleotides in length, or any range within. In some embodiments, oligonucleotides according to the invention, are 10 to 20 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides in length, or any range within.

10 In certain embodiments, the oligonucleotide has a sequence that is complementary to a miRNA or a precursor thereof.

In one embodiment of the composition of the invention, the said oligonucleotide is an antisense oligonucleotide that is at least partially complementary to the sequence of the target miRNA involved in the angiogenesis, said target miRNA being preferentially 15 selected from miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), or a precursor thereof.

20 In another embodiment of the composition of the invention, the said oligonucleotide is an antisense oligonucleotide that is at least partially complementary to the sequence of miR-92a.

The expression "antisense oligonucleotide" refers to an oligonucleotide having a nucleotide sequence complementary to a specific nucleotide sequence (referred to as a 25 sense sequence) and capable of hybridizing with the sense sequence.

"Complementarity" means the nucleotide pairing ability between a first nucleic acid and a second nucleic acid.

In certain embodiments, an antisense oligonucleotide has a nucleotide sequence that is complementary to a microRNA or a precursor thereof, meaning that the sequence of 30 the antisense oligonucleotide is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the complement of a microRNA or precursor thereof, or that the two sequences hybridize under stringent hybridization conditions. Accordingly, in certain embodiments the nucleotide sequence of the antisense oligonucleotide may have one or more mismatched basepairs with respect to its target microRNA or precursor sequence,

and is capable of hybridizing to its target sequence. In certain embodiments, the antisense oligonucleotide has a sequence that is fully complementary to a microRNA or precursor thereof, meaning that the nucleotide sequence of the antisense oligonucleotide is 100% identical of the complement of a microRNA or a precursor thereof.

5 In the context of the present invention, "Complementary" means an antisense oligonucleotide having a nucleotide sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% at least 99%, or 100%, identical to the complement of the nucleotide sequence of miR-92a, or precursor thereof, over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 10 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or 49 nucleotides, or that the two sequences hybridize under stringent hybridization conditions.

15 "Percent complementarity" means the number of complementary nucleotide in a nucleic acid divided by the length of the nucleic acid. In certain embodiments, percent complementarity of an oligonucleotide means the number of nucleotides that are complementary to the target nucleic acid, divided by the length of the oligonucleotide.

20 In one embodiment, the antisense oligonucleotide sequence is "fully complementary" to the sequence of the target microRNA involved in the angiogenesis, preferentially selected from the group comprising miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b), and more preferentially miR-92a, or precursors thereof, which means that each nucleotide of the antisense oligonucleotide is capable of pairing with a nucleotide at each corresponding position in the target microRNA or precursor thereof.

25 In certain embodiment, the antisense oligonucleotide according to the invention has a sequence that is partially or fully complementary to the sequence of:

30 a) miR-92a comprising a sequence selected from the group consisting of SEQ ID No. 21, 22 or 23 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 21, 22 or 23;

b) miR-92b comprising a sequence selected from the group consisting SEQ ID No. 24 or 25 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 24 or 25;

- c) miR-17 comprising a sequence selected from the group consisting SEQ ID No. 26 or 27 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 26 or 27;
- d) miR-503 comprising a sequence selected from the group consisting SEQ ID No. 5 28 or 29 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 28 or 29; and
- e) miR-16 comprising a sequence selected from the group consisting SEQ ID No. 10 30, 31 or 32 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 30, 31 or 32;
- f) miR-374 comprising a sequence selected from the group consisting of SEQ ID No. 33, 34, 35, 36, 37 or 38 or a sequence having at least 90% nucleotide identity with one 15 of SEQ ID No. 33, 34, 35, 36, 37 or 38;
- g) miR-24 comprising a sequence selected from the group consisting of SEQ ID No. 39, 40, 41 or 42 or a sequence having at least 90% nucleotide identity with one of SEQ 15 ID No. 39, 40, 41 or 42;
- h) miR-483 comprising a sequence selected from the group consisting of SEQ ID No. 43 or 44 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 43 or 44;
- i) miR-34 comprising a sequence selected from the group consisting of SEQ ID No. 20 45, 46, 47, 48, 49 or 50 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 45, 46, 47, 48, 49 or 50;
- j) miR-20 comprising a sequence selected from the group consisting of SEQ ID No. 51, 52, 53 or 54 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 51, 52, 53 or 54; and
- k) miR-15 comprising a sequence selected from the group consisting of SEQ ID No. 25 55, 56, 57 or 58 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 55, 56, 57 or 58.

In certain embodiments, the antisense oligonucleotide according to the invention has a sequence that is partially or fully complementary to the sequence of:

- 30 a) mir-92a-1 comprising the sequence SEQ ID No. 1, or a sequence having at least 90% nucleotide identity with SEQ ID No. 1;
- b) mir-92a-2 comprising the sequence SEQ ID No. 2, or a sequence having at least 90% nucleotide identity with SEQ ID No. 2;

- c) mir-92b comprising the sequence SEQ ID No. 3, or a sequence having at least 90% nucleotide identity with SEQ ID No. 3;
- d) mir-17 comprising the sequence SEQ ID No. 4 or a sequence having at least 90% nucleotide identity with SEQ ID No. 4;
- 5 e) mir-503 comprising the sequence SEQ ID No. 5 or a sequence having at least 90% nucleotide identity with SEQ ID No. 5;
- f) mir-16-1 comprising the sequence SEQ ID No. 6, or a sequence having at least 90% nucleotide identity with SEQ ID No. 6; and
- 10 g) mir-16-2 comprising the sequence SEQ ID No. 7, or a sequence having at least 90% nucleotide identity with SEQ ID No. 7;
- h) mir-374a comprising the sequence SEQ ID No. 8, or a sequence having at least 90% nucleotide identity with SEQ ID No. 8;
- 15 i) mir-374b comprising the sequence SEQ ID No. 9, or a sequence having at least 90% nucleotide identity with SEQ ID No. 9;
- j) mir-374c comprising the sequence SEQ ID No. 10, or a sequence having at least 90% nucleotide identity with SEQ ID No. 10;
- 20 k) mir-24-1 comprising the sequence SEQ ID No. 11, or a sequence having at least 90% nucleotide identity with SEQ ID No. 11;
- l) mir-24-2 comprising the sequence SEQ ID No. 12, or a sequence having at least 90% nucleotide identity with SEQ ID No. 12;
- 25 m) mir-483 comprising the sequence SEQ ID No. 13, or a sequence having at least 90% nucleotide identity with SEQ ID No. 13;
- n) mir-34a comprising the sequence SEQ ID No. 14, or a sequence having at least 90% nucleotide identity with SEQ ID No. 14;
- o) mir-34b comprising the sequence SEQ ID No. 15, or a sequence having at least 90% nucleotide identity with SEQ ID No. 15;
- 20 p) mir-34c comprising the sequence SEQ ID No. 16, or a sequence having at least 90% nucleotide identity with SEQ ID No. 16;
- q) mir-20a comprising the sequence SEQ ID No. 17, or a sequence having at least 90% nucleotide identity with SEQ ID No. 17;
- 30 r) mir-20b comprising the sequence SEQ ID No. 18, or a sequence having at least 90% nucleotide identity with SEQ ID No. 18;
- s) mir-15a comprising the sequence SEQ ID No. 19, or a sequence having at least 90% nucleotide identity with SEQ ID No. 19, and

t) mir-15b comprising the sequence SEQ ID No. 20, or a sequence having at least 90% nucleotide identity with SEQ ID No. 20.

In certain embodiments, the antisense oligonucleotide according to the invention has a sequence that is partially complementary to the sequence of the mir-92a-1 (SEQ ID NO: 1).

In certain embodiments, the antisense oligonucleotide according to the invention has a sequence that is fully complementary to the sequence of the mir-92a-1 (SEQ ID NO: 1).

In certain embodiments, the antisense oligonucleotide according to the invention has a sequence that is partially complementary to the sequence of the mir-92a-2 (SEQ ID NO: 2).

In certain embodiments, the antisense oligonucleotide according to the invention has a sequence that is fully complementary to the sequence of the mir-92a-2 (SEQ ID NO: 2).

In one embodiment, the antisense oligonucleotide comprises a modified backbone. Examples of such backbones are provided by morpholino backbones, carbamate backbones, siloxane backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl backbones, riboacetyl backbones, alkene containing backbones, sulfamate, sulfonate and sulfonamide backbones, methyleneimino and methylenehydrazino backbones, and amide backbones.

Morpholino oligonucleotides have an uncharged backbone in which the deoxyribose sugar of DNA is replaced by a six membered ring and the phosphodiester linkage is replaced by a phosphorodiamidate linkage. Morpholino oligonucleotides are resistant to enzymatic degradation and appear to function as antisense agents by arresting translation or interfering with pre-mRNA splicing rather than by activating RNase H.

A modified backbone is typically preferred to increase nuclease resistance. A modified backbone can also be preferred because of its altered affinity for the target sequence compared to an unmodified backbone. An unmodified backbone can be RNA or DNA.

Another suitable antisense oligonucleotide comprises a Peptide Nucleic Acid (PNA), having a modified polyamide backbone. PNA-based molecules are true mimics of DNA molecules in terms of base-pair recognition. The backbone of the PNA is composed of 7V-(2-aminoethyl)- glycine units linked by peptide bonds, wherein the nucleobases are linked to the backbone by methylene carbonyl bonds.

A further suitable backbone comprises a morpholino nucleotide analog or equivalent, in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring. A most preferred nucleotide analog or equivalent comprises a phosphorodiamidate morpholino oligomer (PMO), in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring, and the anionic phosphodiester linkage between adjacent morpholino rings is replaced by a non-ionic phosphorodiamidate linkage.

In yet a further embodiment, an antisense oligonucleotide of the invention comprises a substitution of one of the non-bridging oxygens in the phosphodiester linkage. 10 This modification slightly destabilizes base- pairing but adds significant resistance to nuclease degradation.

A further suitable antisense oligonucleotide of the invention comprises one or more sugar moieties that are mono- or disubstituted at the 2', 3' and/or 5' position such as a -OH; -F; substituted or unsubstituted, linear or branched lower (CI- CIO) alkyl, alkenyl, 15 alkynyl, alkaryl, allyl, aryl, or aralkyl, that may be interrupted by one or more heteroatoms; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; O-, S-, or N-allyl; O-alkyl-O-alkyl, -methoxy, -aminopropoxy; -amino xy; methoxyethoxy; - dimethylaminoxyethoxy; and -dimethylaminoethoxyethoxy.

The sugar moiety can be a pyranose or derivative thereof, or a deoxypyranose or 20 derivative thereof, preferably a ribose or a derivative thereof, or a deoxyribose or a derivative thereof. Such preferred derivatized sugar moieties comprise Locked Nucleic Acid.

An LNA is a modified RNA nucleotide wherein the ribose moiety of LNA nucleotide is modified with an extra bridge connecting 2' and 4' carbons. This enhances the 25 base stacking and pre-organization, and significantly increases the thermal stability. This bridge "locks" the ribose in 3'-endo structural conformation, which is often found in A-form of DNA or RNA. LNA nucleotides used in the present invention can be mixed with DNA or RNA bases in the oligonucleotide whenever desired.

According to the invention, the said antisense oligonucleotide is selected in the 30 group consisting of a ribonucleotide, a deoxyribonucleotide, a small RNA, an antagonir, a LNA, a CDNA, a PNA, a morpholino oligonucleotide or a combination thereof.

In another embodiment, the antisense oligonucleotide can consist of an antagonir.

In a preferred embodiment of the composition of the invention, the said oligonucleotide consists of an antagonir.

Antagomirs are chemically engineered oligonucleotides which are used to silence endogenous microRNA. An antagomir is a small synthetic RNA or DNA that is perfectly complementary to the specific microRNA target with either mispairing at the cleavage site or some sort of base modification to inhibit cleavage. Usually, antagomirs have some sort 5 of modification to make it more resistant to degradation and facilitate cellular internalization. It is unclear how antagomirization (the process by which an antagomir inhibits microRNA activity) operates, but it is believed to inhibit by irreversibly binding the microRNA. Antagomirs are used to constitutively inhibit the activity of specific microRNAs.

10 In an embodiment of the invention, the said antagomir comprises a nucleotide sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous nucleotides complementary to a microRNA, or a precursor thereof, the said microRNA having a sequence selected from the group consisting of SEQ ID No. 1 to 58.

15 In an embodiment of the invention, the said antagomir comprises a nucleotide sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous nucleotides complementary to the mir-92a of sequence selected from the group consisting of SEQ ID No. 1, 2 or 3.

20 In an embodiment of the invention, the said antagomir comprises a nucleotide sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous nucleotides complementary to the miR-92a of sequence selected from the group consisting of SEQ ID No. 21, 22 or 23.

25 In another embodiment, the said antagomir comprises a nucleotide sequence comprising at least 16 contiguous nucleotides complementary to the nucleotides of sequence SEQ ID No. 21.

25 In an embodiment of the invention, the said antagomir possesses a DNA backbone.

30 In said embodiment of the composition of the invention, the said antagomir comprises the sequence SEQ ID No. 59 and modifications excluding base substitutions thereof, and fragments consisting of subsequences of SEQ ID NO: 59 of at least 8 contiguous nucleotides thereof.

30 In another embodiment of the invention, the said antagomir possesses a RNA backbone.

30 In said embodiment of the composition of the invention, the said antagomir comprises the sequence SEQ ID No. 60 and modifications excluding base substitutions

thereof, and fragments consisting of subsequences of SEQ ID NO: 60 of at least 8 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 8 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 9 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 10 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 11 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 12 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 13 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 14 contiguous nucleotides thereof.

In one embodiment, the antagonir according to the invention is a fragment consisting of a subsequence of SEQ ID NO: 59 or 60 of at least 15 contiguous nucleotides thereof.

In another embodiment, the said antagonir of sequence SEQ ID No. 59 or 60 presents at least 1, 2, 3, 4, 5, 6 or 7 modified nucleotide(s) by phosphotioate bond(s) between adjacent nucleotide.

In other embodiment of the invention, the said antagonir can include 2'-O-methyl modified nucleotide, cholesterol group or any similar or equivalent modification.

Generally, if a pharmaceutical formulation containing a nucleic acid, a peptide and a protein is administered orally or parenterally, it is degraded by enzymes in the body, and the efficacy of the pharmaceutical formulation disappears quickly. Various trials have been

made to conquer the problem. One of which is to formulate a long sustained-release injectable.

In practice, research is being conducted on the use of stents as a system for the selective administration of microRNAs. However, rapid endothelialization of the stents 5 could pose a problem with regard to the sustained release of microRNAs, especially for biological processes requiring prolonged gene modulation. In addition, liposomes and nanoparticles have been developed and used *in vivo* but pass to the circulatory system with risk of serious side effects have not been avoided. In addition, no studies have demonstrated efficacy and safety after percutaneous intracoronary administration without 10 previous aortic clamp.

Another aspect of the invention is based on the use of biodegradable and biocompatible microspheres.

According to the invention, it has been designed and manufactured a release system appropriate for localised release of oligonucleotides in the cardiac region, based on the 15 microencapsulation of said oligonucleotides with biocompatible biodegradable polymers. The invention allows to obtain microspheres substantially loaded with oligonucleotides, which have high encapsulation efficiency and no molecule modification/degradation. According to the invention, the purity and quality of the molecule, without adding either a stabilising agent or a retention substance, is preserved, thanks to the manufacturing 20 conditions used, particularly the characteristics of the emulsion created, the concentration of the polymer solution and the relation between the volumes of the phases involved in the microencapsulation process. In addition, the microspheres have an appropriate particle-size distribution to enable them to be retained in the microvessels of the infarcted area without causing arterial emboliation and without being destroyed by macrophage phagocytic 25 action.

An object of the present invention is to provide a sustained-release microsphere, which stably encapsulates a short chain deoxyribonucleic acid or a short chain ribonucleic acid, and is able to inhibit, for a long period, the inhibition of the expression of a specific protein, especially a protein whose inhibition is related to a disease.

30 Generally speaking, “biocompatible” means compatible with living cells, tissues, organs, or systems, and posing no risk of injury, toxicity, or rejection by the immune system. A biocompatible microsphere means that the microsphere, and any degradation products of the microsphere, is non-toxic to the recipient and also presents no significant

deleterious or untoward effects on the recipient's body, such as an immunological reaction at the injection site.

Generally speaking, "biodegradable" means capable of being decomposed by the action of biological agents.

5 A biodegradable microsphere, as defined herein, means the microsphere will degrade or erode in vivo to form smaller chemical species. Degradation can result, for example, by enzymatic, chemical and/or physical processes.

10 Suitable biocompatible, biodegradable polymers include, for example, poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polycaprolactone, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polyacetyls, polycyanoacrylates, polyetheresters, poly(dioxanone)s, poly(alkylene alkylate)s, copolymers of polyethylene glycol and polyorthoester, biodegradable polyurethanes, blends and copolymers thereof.

15 A number of techniques to produce microparticles have been described in the prior art.

The drug release profile for a microparticle is dependent on numerous factors, including physicochemical properties of the used polymers, interactions among polymer-drug-excipients and/or morphology and composition of the resulting microparticles.

20 In order for the microspheres to be retained by the myocardial capillaries they must have very specific size distribution so that their destruction through phagocytosis by macrophages, on the one hand, or embolization of the arteries, on the other, is minimised; microencapsulation using a biodegradable, biocompatible polymer enables controlled release of the product from the initial hours for up to 2-3 weeks, the main period during 25 which post-AMI ventricular remodelling occurs.

30 In the context of the present invention, as the intracoronary route is preferred, the average size of these microspheres makes allowance for the size of the myocardial capillaries; this varies between 5 and 20, preferentially between 5 and 15 microns, to be retained in the cardiac region, and without particles superior to 25 microns to prevent arterial embolization.

In one embodiment of the invention, the said microspheres are presenting a diameter which does not exceed 25 μm .

In one embodiment, 50 to 100% of the microspheres are comprised in the range of 5 to 25 μm and no particles upper than 25 μm

In a preferred embodiment, 60 to 100% of the microspheres are comprised in the range of 5 to 25 μm and no particles upper than 25 μm .

In another preferred embodiment, 70 to 100% of the microspheres are comprised in the range of 5 to 25 μm and no particles upper than 25 μm .

5 In a more preferred embodiment, 80 to 100% of the microspheres are comprised in the range of 5 to 25 μm and no particles upper than 25 μm .

According to the invention, the average diameter of the microspheres is in the range of 5 to 20 μm .

10 According to the invention, the average diameter of the microspheres is in the range of 5 to 15 μm .

In an alternative embodiment, the said microspheres are presenting an average diameter from 8 to 11 μm .

The microspheres according to the invention load a high amount of the said inhibitor of microRNA in a biodegradable and biocompatible polymer to sustained release 15 the drug in the infarcted area.

The inhibitor of microRNA loading is from about 1 to 20% (w/w), preferably from 1 to 15% (w/w), and more preferably 1 to 10 and still more preferably from 5 to 10%. The drug integrity is conserved.

20 In one embodiment, the microspheres according to the invention are incorporating from 1% to 15 % w/w of inhibitor.

In another embodiment, the microspheres according to the invention are incorporating from 5% to 15 % w/w of inhibitor.

Still in another embodiment, the microspheres according to the invention are incorporating from 1% to 10%, preferably from 5% to 10 % w/w of inhibitor.

25 Another characteristic of the invention relates on the nature of the polymer used for the generation of the microspheres.

In an embodiment of the invention, the said microspheres are made of a polymer consisting of poly-d,l-lactide (PLA). In an embodiment, the said microspheres are made of PLA as the sole polymer. In an embodiment, the said microspheres are made of PLA 30 which is blended with one or more other biocompatible polymers.

In another embodiment of the invention, the said microspheres are made of a copolymer consisting of poly-d,l-lactide-co-glycolide (PLGA). In an embodiment, the said microspheres are made of PLGA as the sole polymer. In an embodiment, the said

microspheres are made of PLGA which is blended with one or more other biocompatible polymers.

Still in another embodiment of the invention, the said microspheres are made of a blend of polymers consisting of poly-d,l-lactide-co-glycolide (PLGA) and poly-d,l-lactide (PLA).

By the expression "blend", it must be understood that a mixture of two or more polymers is realized before the dissolution of the said mixture into the same organic solvent.

The man skilled in the art will easily understand that, contrary to the PLGA copolymer, the ratio of lactide:glycolide in the PLA polymer is comprised between 100:0 molar ratio.

Regarding the PLGA copolymer, the ratio of lactide:glycolide in the PLGA polymer is comprised between 50:50 to 95:5 molar ratio.

In a preferred embodiment, the ratio of lactide:glycolide in the PLGA copolymer is comprised between 50:50 to 90:10 molar ratio, and preferentially between 50:50 to 80:20 molar ratio.

In an embodiment of the invention, the inherent viscosity of the polymer is comprised between 0.1 and 0.7 dl/g.

In a preferred embodiment, the inherent viscosity of the polymer is comprised between 0.15 and 0.7 dl/g, preferentially from 0.15 to 0.5 dl/g.

This aspect is of interest in the sense that inherent viscosity is related with the polymer molecular weight and, therefore, influences in the inhibitor release rate from the polymeric microspheres.

Accordingly, it is also an object of the present invention to provide a method for producing a microencapsulated inhibitor of miR-92a which does not include any adjuvant and which consists of a single population of particles in terms of polymeric composition.

Thus, another aspect of the invention is a method for microencapsulating an inhibitor of microRNA in polymeric microspheres, comprising: (a) dissolving the inhibitor of microRNA in purified water, without any stabilizer (b) dissolving polymer in an organic solvent; (c) adding (a) to (b) to produce a first emulsion; (d) adding the emulsion of step (c) to an aqueous solution containing a surfactant and an osmotic agent to produce a second emulsion; (e) hardening and harvesting the resulting microspheres of step (d); and (f) drying.

More particularly, the invention also relates to a method for producing a composition as above described, characterized in that it comprises the following steps:

- a) dissolving the inhibitor of miRNA in purified water, without any stabilizer;
- b) dissolving polymer in an organic solvent;
- 5 c) adding (a) to (b) to produce a first emulsion;
- d) adding the emulsion of step (c) to an aqueous solution containing a surfactant and an osmotic agent to produce a second emulsion; and
- e) hardening and harvesting the resulting microspheres of step (d); and
- f) drying the obtained microspheres.

10 Another aspect of the invention consists of the use of the composition according to the invention in the treatment of the myocardial infarction.

In other word, the invention relates to a composition comprising an effective amount of at least one inhibitor of microRNA, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible 15 microspheres for use in the treatment of myocardial infarction.

In a preferred embodiment, the said myocardial infarction consists of the acute myocardial infarction.

Still another aspect of the invention relates to a method of reversing or preventing ventricular remodelling in a subject in need thereof comprising administering to said 20 subject an effective amount of a composition as above described.

In other word, the invention relates to a composition comprising an effective amount of at least one inhibitor of microRNA, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres for use in a method of reversing or preventing ventricular remodelling in a 25 subject in need thereof.

As already mentioned, the composition according to the invention is suitable for an administration by intracoronary route.

For administration by intracoronary route, the microspheres must be suspended in an appropriate vehicle, either a saline solution (PBS) with or without a surfactant or in 30 another appropriate vehicle for intravenous administration. Suitable dispersants include, for example, surfactants such as polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 60, carboxymethylcellulose, or polysaccharides such as sodium alginate; it is also possible add an isotonizing agent such as sodium chloride, mannitol, sorbitol or glucose, for example. Given the size of coronary arteries, the concentration of

microspheres in the administration medium is adjusted in order to limit blood flow alteration and prevent the risk of arterial embolization. This concentration can vary between 0.05% and 1%, preferably between 0.1% and 0.5%. Administration can be by a single injection or repeated injections, followed optionally by a saline injection. The 5 administration could be carried out after the percutaneous coronary angioplasty, without limitation, using the same catheter.

The method of the invention is characterized in that said administration consists of an administration by intracoronary route.

This aspect is of particular interest as it addresses several presupposed limitations 10 of direct intravenous administration of compounds such as oligonucleotide like antagonir. Among other presupposed limitation, it can be mentioned i) low-level biosafety due to the ubiquity and low organ specificity of miRNAs, ii) high doses and repeated injections for the microRNA inhibitor to produce its effect, and iii) high theoretical cost of the calculated intravenous dose.

15 Surprisingly, as it will be apparent after the reading of the following examples, all these issues are addressed by the invention.

More particularly, it is demonstrated that:

a) it is possible to selectively administer the encapsulated antagonir in the artery 20 supplying the diseased tissue (see Example 5);
b) microspheres are retained in the coronary. (see Example 6);

c) intra-arterial administration of microspheres is used for tumour embolization, enabling permanent blood flow interruption and preventing tumour progression, optionally 25 in combination with active release substances. Taking into consideration these elements, the existence of the risk of embolization was considered. For this reason, studies were designed with the objective of ascertaining that the microspheres cause no damage to cardiac muscle or produce any significant alterations in coronary flow rate. (see Example 7);

d) good stability of the inhibitor of microRNA in the vehicle and sustained release 30 of said inhibitor from microspheres; this is demonstrated by its biological effect while inhibiting microRNA for up to 10 days after it is administered (Example 8);

e) administration of microspheres with the miRNA inhibitor promotes contractile recovery of damaged tissue and prevents the occurrence of adverse post-infarction 35 remodelling. (see Example 9);

f) with localised administration of microspheres, the inhibitor dose could be reduced to a single injection, which would presume a significant reduction of potential side effects and a clear reduction in cost.

The availability of an appropriate vehicle/system for the controlled administration, 5 delivery and release of microRNA inhibitors according to the invention has the following advantages:

- Enhanced biosafety, since bio-distribution of the drug by tissue and organs that are not the treatment target, is limited
- Avoids repeated intravenous injections i) reduces hospital admissions and 10 outpatient hospital visits, by enhancing the quality of patient support, ii) avoids the need for prolonged mainlining for drug administration as well as potential risks resulting from this and iii) minimizes the risks inherent in intravenous administration of products (infections, localised reactions ...)
- Dose reduction allows the reduction in related dose-dependent adverse effects
- Reduction of costs due to a reduction in the doses required as well as the staff and 15 equipment required for repeated injections

In another embodiment, the invention relates to a population of biodegradable and biocompatible microspheres for use in the treatment or prevention of ventricular remodelling after myocardial infarction, wherein said microspheres:

- have an average diameter comprised between 5 and 15 μm ;
- are made of poly-d,l-lactide-co-glycolide (PLGA) ; poly-d,l-lactide (PLA) or a blend thereof;
- are incorporating from 1% to 10 % w/w of a therapeutic agent capable of preventing ventricular remodelling

25 wherein said therapeutic agent consists of an inhibitor of a microRNA involved in angiogenesis, preferentially a microRNA selected from the group consisting of miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-30 24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b) and more preferentially miR-92a, or a precursor thereof, wherein said inhibitor of microRNA is preferentially an antagonir.

The invention also relates to a kit comprising at least i) a composition and/or microspheres according to the invention and ii) a syringe or vial or ampoule in which the composition is disposed.

In an embodiment, the kit of the invention further comprises a solvent disposed in a solvent container. The solvent container may be a vial, an ampoule or a prefilled syringe

The microspheres and the solvent may be disposed in a double compartment prefilled syringe.

In an embodiment, the kit of the invention may comprise the microspheres in a vial and the solvent in a separate vial.

10 In an embodiment, the kit of the invention may comprise the microspheres in a vial and the solvent in a separate ampoule.

In an embodiment, the kit of the invention may comprise the microspheres in a vial and the solvent in a prefilled syringe.

15 In an embodiment, the kit of the invention may comprise the microspheres in a prefilled syringe and the solvent in a separate vial.

In an embodiment, the kit of the invention may comprise the microspheres in a prefilled syringe and the solvent in a separate ampoule.

In an embodiment, the kit of the invention may comprise the microspheres and the solvent separately in a double compartment syringe.

20 The invention will be better understood in respect to the following examples.

Example 1: Preparation of Microspheres loaded with antagonir-92a

Microspheres were prepared by w/o/w emulsion/solvent evaporation method using 25 a 50:50 PLGA copolymer, intrinsic viscosity of about 0.2 dL/g, which contains free carboxyl end groups. 3 ml of methylene chloride were added to 0.6 g of PLGA. 0.3 ml of a concentrated solution of Antagonir-92a (I-Ssc-miR-92a; molecular mass: 5366 g/mol (also referred as Da); sequence: CCGGGACAAGTGCAAT; DNA Bases: 9; LNA Bases: 7; fabricant: IDT (Exiqon)) (222 mg/ml) in purified water was added to the PLGA organic 30 solution and emulsified by sonication for 20 s. This primary emulsion was added to an external phase consisting of an aqueous solution of 1% (w/v) polyvinyl alcohol and 1% (w/v) of sodium chloride and homogenised for 60 s at about 10300 rpm. The second emulsion (w/o/w) obtained was added to a volume of purified water and the methylene chloride was allowed to evaporate by stirring. The obtained microspheres were collected

by centrifugation, washed twice with purified water, and then freeze dried. Average diameter of microspheres was 9 μm , (82% between 5-25 μm and 0% upper 25 μm) while encapsulation efficiency was 74%.

A picture of the obtained microspheres is represented in Figure 1.

5 Figure 2 illustrates the distribution of the microsphere size.

Example 2: Preparation of Microspheres loaded with RNA

Microspheres were prepared by w/o/w emulsion/solvent evaporation method using a 50:50 PLGA copolymer, intrinsic viscosity of about 0.2 dL/g, which contains free carboxyl end groups. 3 ml of methylene chloride were added to 0.6 g of PLGA. 0.3 ml of a concentrated solution of RNA (222 mg/ml) (RNA Sigma 5000-10000Da) in purified water RNAsa free was added to the PLGA organic solution and emulsified by sonication for 20 s. This primary emulsion was added to an external phase consisting of an aqueous solution RNAsa free of 1% (w/v) polyvinyl alcohol and 5% (w/v) of mannitol and homogenised for 15 60 s at about 10300 rpm. The second emulsion (w/o/w) obtained was added to a volume of purified water RNAsa free and the methylene chloride was allowed to evaporate by stirring. The obtained microspheres were collected by centrifugation, washed twice with purified water RNAsa free, and then freeze dried. Average diameter of microspheres was 10 μm , (86% between 5-25 μm and 0% upper 25 μm) while encapsulation efficiency was 20 73%.

Example 3: Preparation of placebo Microspheres

Microspheres were prepared by w/o/w emulsion/solvent evaporation method using a 50:50 PLGA copolymer, intrinsic viscosity of about 0.2 dL/g, which contains free carboxyl end groups. 3 ml of methylene chloride were added to 0.6 g of PLGA. 0.3 ml of purified water was added to the PLGA organic solution and emulsified by sonication for 20 s. This primary emulsion was added to an external phase consisting of an aqueous solution of 1% (w/v) polyvinyl alcohol and 1% (w/v) of sodium chloride and homogenised for 60 s at about 10300 rpm. The second emulsion (w/o/w) obtained was added to a volume of purified water and the methylene chloride was allowed to evaporate by stirring. The obtained microspheres were collected by centrifugation, washed twice with purified water, and then freeze dried. Average diameter of microspheres was 7 μm , (84% between 5-25 μm and 0% upper 25 μm).

Example 4: Preparation of Microspheres loaded with albumin fluorescein isothiocyanate

Microspheres were prepared by w/o/w emulsion/solvent evaporation method using a 50:50 PLGA copolymer, intrinsic viscosity of about 0.2 dL/g, which contains free carboxyl end groups. 1 ml of methylene chloride was added to 0.2 g of PLGA. 0.1 ml of an albumin fluorescein isothiocyanate aqueous solution (20 mg/ml) was added to the PLGA organic solution and emulsified by sonication for 15 s. This primary emulsion was added to an external phase consisting of an aqueous solution of 1% (w/v) polyvinyl alcohol and 1% (w/v) and homogenised for 60 s at about 10300 rpm. The second emulsion (w/o/w) obtained was added to a volume of purified water and the methylene chloride was allowed to evaporate by stirring. The obtained microspheres were collected by centrifugation, washed twice with purified water, and then freeze dried. Average diameter of microspheres was 9 μ m, (91% between 5-25 μ m and 0% upper 25 μ m).

15 Example 5: Study of selective administration in the artery supplying the target tissue

After triggering an AMI in a Large White pig, 30 mg of microspheres containing fluorescent albumin, prepared as indicated in example 4, were administered by intra-coronary route, by means of a 2.5/12 coaxial balloon positioned in the artery responsible for the AMI, which supplies the infarcted area. The microspheres were suspended *in situ* in 10 ml of normal saline solution containing Tween-80; administration was performed in 2 consecutive injections of 5 ml, each followed by 5 ml of normal saline solution. Experiments showed that the encapsulated antagonir can be selectively administered in the artery supplying the diseased tissue.

25

Example 6: Study of retention of the microspheres in the capillaries of the diseased tissue without allowing outflow into the bloodstream

On a pig model, 4 experiments were conducted by administering by intra-coronary route through a coaxial balloon positioned in the medial anterior descending branch, 2 injections with 5 ml each of fluorescent microspheres prepared according to example 4. The 4 animals were euthanized and myocardial samples of the tissue adjoining the anterior descending branch and the control tissue irrigated by other coronary arteries were obtained. The samples were observed through an optical fluorescence microscope and the presence

of microspheres retained in the capillaries of the damaged cardiac muscle as well as their absence in the control tissue was demonstrated.

To rule out systemic biodistribution, in two of the previous animals, besides ischemic and control myocardial tissue, 5 replicate samples from lung, spleen and liver were obtained and visualized by optical microscopy with light B. Fluorescence was exclusively detected in anterior myocardial wall. This analysis revealed that microspheres are retained in the heart avoiding systemic release of antagonir92a (reduction of side effects).

10 **Example 7: Study of retention of microspheres in the capillaries of diseased tissue without damaging the target tissue itself**

Experiments were conducted to investigate the potential local heart toxicity and the therapeutic safety range of dose. To detect local ischemic damage to the cardiac muscle 2 paired piezoelectric crystals, which are highly sensitive in their ability to detect ischemia 15 were employed. When cardiac muscle tissue is affected by ischemia, the remaining tissue becomes dyskinetic and swells; this, along with the blood pressure produced by the remaining contiguous healthy tissue causes the microcrystals to separate and move further away from each other. In two pigs after performing a thoracotomy and a pericardectomy two pairs of microcrystals were inserted, one control pair in the lateral region and one pair 20 in the anterior region supplied by the anterior descending branch, through which the microspheres were administrated. For each pair of medium crystals the distance between them at two points during the cardiac cycle was measured: at end-diastole (EDL) and end-systole (ESL). The relation between EDL and ESL is expressed by the parameter SS 25 (systolic shortening: (EDL – ESL) / EDL. When the left ventricular contraction is completely dissipated EDL = ESL and SS = 0. The normal values range between 0.2 ± 0.1 . As shown in the attached illustration, minimal and transient oscillations after each injection 30 lasting a few seconds were induced with the dose of the study, corresponding to the first and second injections. Furthermore and surprisingly, no local side effects were observed with repeated intracoronary injections of fluorescent microspheres prepared according to example 4 reaching 14 times the dose of the study. No limiting maximum dose was associated with irreversible ischemic damage, hemodynamic repercussion or arrhythmias.

In addition, to detect changes in coronary flow a flow sensor was positioned in middle LAD measuring coronary flow. No significant changes in coronary flow were observed after intracoronary injections.

Results are illustrated by Figure 3 wherein 120mg of microspheres were injected and by Figure 4 wherein 240 mg of micropsheres were injected.

5 **Example 8: Study of the molecular effect of a single intra-coronary injection of microspheres with a small antagomir dose**

In order to demonstrate that small doses of microencapsulated antagomir could produce a molecular response, the miR-92a expression in vivo, in ischemic and control tissue, was measured after intracoronary encapsulated antagomir-92a administration. In 3 pigs, 60 mg of microspheres containing antagomir-92a prepared according to example 1 10 (0.1 mg/Kg) were delivered in LAD. Animals were euthanized at one, three and 10 days after treatment and expression of miR-92a and endogenous microRNA as controls (miR-123, 203, and 126) were quantified in 2 replicate infarcted and control samples by total RNA isolation and real-time quantitative RT-PCR using specific primers (see Figure 5).

15 In infarcted tissue, miR-92a expression resulted down-regulated by 8-fold in comparison with control tissue whereas expression of endogenous miRs was not affected by the treatment. The inhibition began to be present as early as 1 day and it was still present at day 10, with 5 times lower expression levels than in the control area.

20 No significant regulation was detected in endogenous miRs. These results reveals that the vehicle/system provides adequate conditions for enabling controlled delivery and release of antagomir-92a, thereby producing a sustained inhibition of microRNA-92a with a single intracoronary administration.

These results, represented in Figure 6, also confirm that the antagomir is not degraded during the microsphere manufacturing process.

25 **Example 9: Study of the biological effect of a single intra-coronary injection of microspheres containing low doses of antagomir**

In order to demonstrate whether the molecular effect of microsphere-transported antagomir-92a is accompanied by a biological effect, a pre-clinical study was conducted with 26 adult minipigs. The purpose of this study was to investigate whether inhibition of 30 mir-92a by selective intracoronary encapsulated antagomir-92a administration leads to enhancement of angiogenesis in infarcted area, and thus preventing the occurrence of ventricular remodelling.

3 formulations were administered:

- Saline solution (control formulation)

- Placebo microspheres prepared according to example 3
- Antagomir-92a microspheres prepared according to example 1, at one antagomir dose of 3 mg /minipig.

4 weeks after treatment, significant higher vascular density in the necrotic area was 5 detected in those animals receiving encapsulated antagomir-92a compared to controls, thereby confirming the proangiogenic activity of antagomir-92a observed in previous study (161.57±58.71 vs 68.49±23.56 in placebo group vs 73.91±24.97 in saline group, p=0.001) ii) the vascular density (see Figure 7).

Microvascularity increased within both, the infarct zone and the peri-infarct rim. 10 Lower microvascular resistance index in those treated animals was consistently demonstrated (200.67±104.46 vs 511.73±202.1 in controls, p=0.007) and it was significantly correlated with vascular density (R^2 0.41, p=0.02). (see Figure 8).

The baseline microcirculatory resistance (baseline MR) and the true 15 microcirculatory resistance (TMR (hyp)) were significantly lower in the treated group compared with controls (7.47±1.33 vs 19.62±2.98, p=0.005 and 5.0±1.15 vs 14.49±2.4, p= 0.006 respectively). Baseline and true microcirculatory resistance were significantly correlated with vascular density (R^2 0.35, p=0.033 and R^2 0.31, p=0.047 respectively (see Figure 9).

These data indicate that encapsulated antagomir-92a induces sustained 20 angiogenesis in vivo.

Having found growth vessels, its potential benefits in healing process that occurs after an AMI was therefore further investigated. To determine the effects of encapsulated 25 antagomir-92a on ventricular remodelling, morphological and structural parameters by ex vivo magnetic resonance imaging (CMR) and functional parameters analysed by intravascular echocardiography (IVE), in the treated and non-treated groups were compared. Significant more percentage of animals with anterior and septoapical dyskinesia was present in IVE in controls (p=0.03) (see notably Figure 10) with also significant higher thinning of the injured ventricular wall and adverse remodelling morphometry changes in left ventricle in ex-vivo CMR in comparison with treated animals (Table 3).

30 More particularly, Figure 10 illustrates the results of the analysis of regional wall motion dysfunction by intravascular echocardiography (IVE). IVE was performed by using a Vivid Q ultrasound imaging machine (GE Healthcare, Belford, UK) and an AcuNav 10F ultrasound catheter (Siemens) placed in the apex of the right ventricle.

The results of the study show that the administration of antagonir-92a microspheres is associated with a statistically significant reduction in adverse remodelling following acute myocardial infarction.

Table 3: Parameters of left ventricular remodelling in CMR

	Saline (N=6)	Placebo ME (N=5)	Antagonir-92a ME (N=6)	P
Number of infarcted CMR slices	4.8±0.3	4.8±0.4	5.3±0.2	0.38
T _{maxinfarctedwall} , mm	6.07±0.9	5.61±0.5	9.01±0.6	0.006
T _{normal posterior wall} , mm	13.23±0.5	13.52±1.8	11.82±0.7	0.49
Percentage of minimum thinning, %	54.79±4.9	56.74±4.1	22.71±5.5	0.000
T _{mininfarctedwall} , mm	3.17±0.4	4.02±0.9	4.35±0.5	0.33
Percentage of maximum thinning, %	76.40±2.1 8	69.86±4.72	62.54±4.19	0.05
Length of the thinning wall, mm	32.2±1.8	31.7±4	20.5±3.6	0.03
D _R /D _N	1.93±0.2	2.02±0.2	1.29±0.1	0.03
D _N , mm	14.88±0.6 8	13.78±1.59	17.5±1.37	0.12
Adverse remodeling% (n)	83.3 (5)	80 (4)	16.7 (1)	0.03

Encapsulated antagonomir-92a prevents adverse left ventricular remodelling 1 month after acute myocardial infarction. The different remodelling parameters calculated in all infarcted slices of ex-vivo CMR in each minipig were determined. Representative L2 slice (being L1 the apex) of four minipigs are shown. $T_{\text{max infarcted wall}}$ = mean maximum infarcted wall thickness calculated as \sum of the maximum infarct wall thickness in each slice divided by the number of affected slices; $T_{\text{normal posterior wall}}$ = mean thickness of normal posterior wall measured just beside the insertion of posterior papillary muscle calculated as \sum of the wall posterior thickness in each affected slice divided by the number of affected slices; mean percentage of minimum thinning calculated as $[100 - (T_{\text{max infarcted wall}}/T_{\text{normal posterior wall}} \times 100)]$; $T_{\text{min infarcted wall}}$ = mean minimum infarcted wall thickness calculated as \sum of the minimum infarct wall thickness in each affected slice divided by the number of affected slices; mean percentage of maximum thinning calculated as $[100 - (T_{\text{min infarcted wall}}/T_{\text{normal posterior wall}} \times 100)]$; D_R : mean maximal diameter between infarcted wall and contralateral normal wall calculated as \sum of the maximal diameter between infarcted wall in each infarcted slice divided by the number of affected slices; D_N : mean maximal diameter between normal walls, forming a right angle with D_R and drawn nearest the center of the ventricular cavity, calculated as \sum of the maximal diameter between normal walls in each infarcted slice divided by the number of affected slices; D_R/D_N : mean sphericity index calculated as \sum of the D_R/D_N of each infarcted slice divided by the number of affected slices. Data of the table are expressed as the mean \pm s.e.m.

The results of a representative CMR show that :

A: Cardiac NMR and IVE of minipig 14 (death immediately after induction of AMI): Owing to the occurrence of death immediately following the AMI, there was not enough time for the remodelling process to be triggered. This is why a concentric left ventricle was seen to have similar dimensions in all of the segments.

B: Cardiac NMR and IVE of the minipig 20 to 30 days post-AMI: evidence of adverse ventricular remodelling: One month after the AMI, extreme emaciation of the anterior and septal sections was observed on the CMR as well as an aneurysm formation with dyskinesia on the IVE which is typical of post-AMI adverse remodelling.

C: Cardiac NMR and IVE of the minipig 22 to 30 days post-AMI: no ventricular remodelling: One month after AMI, slight reduction of the parietal region in the anterior and septal areas was observed without aneurysm formation and without dyskinesia in the IVE. This is a typical case of favourable repair reactions after AMI.

Example 10: Study of the induction of vascular tumours or effects in short-term mortality of encapsulated antagomir-92a

No vascular tumors were observed in necropsy analysis performed to all animals, thereby suggesting the absence of ectopic systemic suppression of microRNA-92a in other organs at distance. The mortality of the study was of 23 %. No differences were observed in short-term mortality. Only one minipig allocated to encapsulated antagomir92a died (p=0.39).

Table 4

N= 26	Saline (n=9)	Placebo ME (n=9)	Antagomir-92a ME (n=8)
1 month follow-up	6	7	7
Death	3	2	1

10

Example 11: Study of the proarrhythmic profile of encapsulated antagomir-92a.

In order to know the arrhythmogenic potential of encapsulated antagomir-92a, all arrhythmic events during the procedures were recorder and analyzed by Collect 5S software (GE). Moreover, to address this issue, an insertable loop recorder was randomly implanted in 10 of the 26 minipigs of the study to detect potential episodes of arrhythmia until sacrifice, at one month postinfarction and treatment. No higher number of maligne tachyarrhythmias nor bradiarrhythmias were observed in treated group in comparison with controls, indicating that intracoronary encapsulated antagomir-92a doesn't exert a proarrhythmic effect.

Table 5: Arrhythmias detected during the study

	Saline (n=9)	Placebo ME (n=9)	Antagomir-92a ME (n=8)	p
<i>Ischemic phase (n= 26)</i>				
No arrhythmias, n(%)	2 (22.2)	0	1 (12.5)	0.37
Arrhythmias, n(%)	7 (77.8)	(100)	7 (87.5)	
PVC, n	5	7	5	
NSVT, n	0	1	1	
Ventricular fibrillation, n	3	3	3	
<i>Reperfusion phase (n=26)</i>				
No arrhythmias, n(%)	5 (55.6)	3 (33.3)	3 (37.5)	0.6
Arrhythmias, n(%)	4 (44.4)	6 (66.7)	5 (62.5)	
Sinusal pauses, n	1	1	0	
1	1	0	0	
Nodal rhythm,n	0	2	1	
IVR, n	4	3	3	
0	0	0	1	
PVC, n				
NSVT, n				
<i>During 30 days after AMI (n=10)</i>				
<i>Implantable loop recorder</i>	n=4	n=3	n=3	0.88
No arrhythmias, n(%)	0 (0)	0 (0)	0 (0)	0.38
Arrhythmias, n(%)	2 (50)	3 (100)	3 (100)	
Sinusal taquicardia	2	3	3	
0	1	0	0	
Sinusal pausa	0	0	1	
PVC or PSVC	2 (50)	0	0	
Not assessable				

PVC: premature ventricular complexes, NSVT: non-sustained ventricular

5 taquicardia,

IVR: idioventricular rhythm,

PSVC: premature supraventricular complexes

AMI: acute myocardial infarction

Example 12: evaluation of the effects of encapsulated antagonir 92a and non encapsulated antagonir-92a on the expression of miR92a *in vitro*.

12.1: Material and Method

5 **a. Cells**

The human umbilical vein cell line, EA.hy926, established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of lung cells A549 (ATCC® CRL-2922™) has been used.

b. Treatment

10 Approximately 500 000 EA.hy926 cells were seeded onto six well plates and incubated under standard condition (37°C, 5% CO2) in RPMI 1640 supplemented in 10% fetal bovine serum (FBS) and 2 mM L-glutamine (Sigma, L'Isle d'abeau, France) Medium was then replaced by fresh completed RPMI medium containing the respective antagonirs and their respective controls (PBS or microspheres).
15 EA.hy926 cells have been treated with either, antagonir 92a (free and three batches of Antagonir92a microspheres), encapsulated antagonir 17 or encapsulated antagonir 20 at 10 and 150 nM. Cells were incubated for a further 24 h before harvesting for RNA extraction. Total RNA was extracted and the expression of miRNAs was quantified by means of quantitative RT-PCR.

20 **c. RNA Extraction**

miRNAs were isolated from EA.hy926 cells and mini-pig tissues using Qiagen RNeasy mini-preps (ref. 74106) and RNeasy+ universal kits (ref. 73404), respectively, according to manufacturers instructions (Qiagen, Courtaboeuf, France). The quantity and purity of extracted RNA were assessed using a NanoDrop ND 1000 spectrophotometer 25 (Labtech International, Paris, France).

d. Reverse transcription of miRNAs

miRNAs were reverse-transcribed, using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, ref. 4366596), in a final volume of 15 µl containing 5 ng of total RNA and the specific miRNA probe. The samples were incubated at 16°C for 30 min and 42°C for 30 min, and reverse transcriptase was inactivated by heating at 85°C for 5 min and cooling at 4°C forever.

e. Real-Time RT-PCR

Theoretical Basis. Quantitative values are obtained from the Ct number at which the increase in signal associated with exponential growth of PCR products starts to be detected (using the QuantStudio 6 and 7 Flex Software, according to the manufacturer's

manual). To control the differences in amounts of starting material, the data were normalized to the geometric mean of 2 endogenous controls (miRNA103 and miRNA191) which expression levels have been empirically shown not to change as a function of treatment. Value of the target miRNA was subsequently normalized such that the value of 5 the target miRNA in the control equals a value of 1. Results were expressed using the $\Delta\Delta Ct$ calculation method (RQ analysis software, Applied Biosystems®).

10 **PCR Amplification.** All PCR reactions were performed using a QuantStudio™ 6 Flex Real-Time PCR System and TaqMan probes (Applied Biosystems®). The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 min and 45 cycles at 95°C for 15 s and 65°C for 1 min. Samples were tested in duplicate.

12.1: Results

15 miR-92a expression is inhibited by both antagonir-92a free and encapsulated at 10 nM with an approximate 90% reduction.

20 miR-92a expression is undetectable after both antagonir-92a free and encapsulated at 150 nM.

Neither miR-17 or miR-20a expression was significantly reduced by antagonir-92a treatment.

25 These data are summarized in Figure 11.

Example 13: evaluation *in vitro* of the effects of three encapsulated antagonirs (antagonir 17, 20a and 92a) on their respective expression of miRs.

13.1 Preparation of Microspheres loaded with antagonir-17

25 Microspheres were prepared by an emulsion/solvent evaporation method using a 50:50 PLGA copolymer (i.v. 0.2 dL/g). A solution of antagonir-17 (HSA-miR-17-5p; molecular mass: 5305Da; sequence: CTGCACTGTAAGCACT; from Exiqon) was emulsified in the PLGA organic solution. The obtained emulsion was in turn incorporated 30 in a dispersing aqueous phase and homogenised to obtain the desired particle size. Finally, after the solvent evaporation, the obtained microspheres were freeze-dried. The average diameter of microspheres was 10 μ m and the antagonir-17 content was 7.3%.

13.2 Preparation of Microspheres loaded with antagonir-20a

Microspheres were prepared by an emulsion/solvent evaporation method using a 50:50 PLGA copolymer (i.v. 0.2 dL/g). A solution of antagonir-20a (HSA-miR-20a; molecular mass: 5289Da; sequence: CTGCAC TATAAGCACT; from Exiqon) was 5 emulsified in the PLGA organic solution. The obtained emulsion was in turn incorporated in a dispersing aqueous phase and homogenised to obtain the desired particle size. Finally, after the solvent evaporation, the obtained microspheres were freeze-dried. The average diameter of microspheres was 10 μ m and the antagonir-20a content was 6.8 %.

10

13.3 Results

Material and method is the same as in Example 12.

- miR-17 is inhibited at 76% by encapsulated antagonir-17 at 10 nM. miR17 expression is totally abolished by encapsulated antagonir-17 treatment at 150 nM.
- miR-20a is inhibited at 7% by encapsulated antagonir-20a treatment at 10 nM 15 and at 87% by encapsulated antagonir-20a treatment at 150 nM.

Results are represented in Figure 12.

Example 14: evaluation *in vitro* of three batches of Antagonir92a microspheres, with the characteristics of load, size and ratio Lactide/Glycolide.

20

14.1 Preparation of Microspheres with low antagonir-92a loading (L13250 : Polymer : RESOMER RG502H)

Microspheres were prepared by an emulsion/solvent evaporation method using a 50:50 PLGA copolymer (i.v. 0.2 dL/g) as described in example 1 but using lower initial 25 amount of drug and a higher agitation speed in order to prepare smaller microspheres with low antagonir-92a content. The average diameter of microspheres was 7 μ m and the antagonir-92a content was 1.5 %.

30

14.2 Preparation of Microspheres with high antagonir-92a loading (L13262 : Polymer : RESOMER RG502H)

Microspheres were prepared by an emulsion/solvent evaporation method using a 50:50 PLGA copolymer (i.v. 0.2 dL/g) as described in example 1 but using higher initial amount of drug and a lower agitation speed in order to prepare bigger microspheres with

high antagonir-92a content. The average diameter of microspheres was 15.6 μm and the antagonir-92a content was 9.8 %.

14.3 Preparation of Microspheres loaded with antagonir-92a using a long-

5 lasting polymer (L13230: Polymer : LACTEL B6006)

Microspheres were prepared by an emulsion/solvent evaporation method as described in example 1 but using a 85:15 PLGA copolymer with a high molecular weight (i.v. 0.64 dL/g), intended for a slow drug release. The average diameter of microspheres was 12 μm and the antagonir-92a content was 3.1%.

10

14.4 Results

The three batches of antagonir-92a microspheres, with the characteristics of load, size and ratio Lactide/Glycolide have been tested.

According to microsphere content L13250 has been tested at 2 and 30 nM, L13262 15 at 14 and 210 nM, and L13230 at 4 and 66 nM,

L13250, L13262 and L13230 totally abolished miR92a expression.

CLAIMS

1. Composition comprising an effective amount of at least one inhibitor of a
5 miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is
microencapsulated into polymeric biodegradable and biocompatible microspheres.
2. The composition of claim 1, wherein said miRNA is selected in the family
comprising miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503,
10 miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b
and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 (including
miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15
(including miR-15a and miR-15b).
- 15 3. The composition of claim 1, wherein said miRNA consists of the mature:
 - a) miR-92a comprising a sequence selected from the group consisting of SEQ ID
No. 21, 22 or 23 or a sequence having at least 90% nucleotide identity with one of SEQ ID
No. 21, 22 or 23;
 - b) miR-92b comprising a sequence selected from the group consisting of SEQ ID
20 No. 24 or 25 or a sequence having at least 90% nucleotide identity with one of SEQ ID No.
24 or 25;
 - c) miR-17 comprising a sequence selected from the group consisting of SEQ ID
No. 26 or 27 or a sequence having at least 90% nucleotide identity with one of SEQ ID No.
26 or 27;
 - 25 d) miR-503 comprising a sequence selected from the group consisting of SEQ ID
No. 28 or 29 or a sequence having at least 90% nucleotide identity with one of SEQ ID No.
28 or 29;
 - e) miR-16 comprising a sequence selected from the group consisting of SEQ ID
No. 30, 31 or 32 or a sequence having at least 90% nucleotide identity with one of SEQ ID
30 No. 30, 31 or 32;
 - f) miR-374 comprising a sequence selected from the group consisting of SEQ ID
No. 33, 34, 35, 36, 37 or 38 or a sequence having at least 90% nucleotide identity with one
of SEQ ID No. 33, 34, 35, 36, 37 or 38;

- g) miR-24 comprising a sequence selected from the group consisting of SEQ ID No. 39, 40, 41 or 42 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 39, 40, 41 or 42;
- h) miR-483 comprising a sequence selected from the group consisting of SEQ ID No. 43 or 44 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 43 or 44;
- i) miR-34 comprising a sequence selected from the group consisting of SEQ ID No. 45, 46, 47, 48, 49 or 50 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 45, 46, 47, 48, 49 or 50;
- j) miR-20 comprising a sequence selected from the group consisting of SEQ ID No. 51, 52, 53 or 54 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 51, 52, 53 or 54; and
- k) miR-15 comprising a sequence selected from the group consisting of SEQ ID No. 55, 56, 57 or 58 or a sequence having at least 90% nucleotide identity with one of SEQ ID No. 55, 56, 57 or 58.

4. The composition of claim 1, wherein the said precursor of miRNA consists of:

- a) mir-92a-1 comprising the sequence SEQ ID No. 1, or a sequence having at least 90% nucleotide identity with SEQ ID No. 1;
- b) mir-92a-2 comprising the sequence SEQ ID No. 2, or a sequence having at least 90% nucleotide identity with SEQ ID No. 2;
- c) mir-92b comprising the sequence SEQ ID No. 3, or a sequence having at least 90% nucleotide identity with SEQ ID No. 3;
- d) mir-17 comprising the sequence SEQ ID No. 4 or a sequence having at least 90% nucleotide identity with SEQ ID No. 4;
- e) mir-503 comprising the sequence SEQ ID No. 5 or a sequence having at least 90% nucleotide identity with SEQ ID No. 5;
- f) mir-16-1 comprising the sequence SEQ ID No. 6, or a sequence having at least 90% nucleotide identity with SEQ ID No. 6; and
- g) mir-16-2 comprising the sequence SEQ ID No. 7, or a sequence having at least 90% nucleotide identity with SEQ ID No. 7
- h) mir-374a comprising the sequence SEQ ID No. 8, or a sequence having at least 90% nucleotide identity with SEQ ID No. 8

- i) mir-374b comprising the sequence SEQ ID No. 9, or a sequence having at least 90% nucleotide identity with SEQ ID No. 9
- j) mir-374c comprising the sequence SEQ ID No. 10, or a sequence having at least 90% nucleotide identity with SEQ ID No. 10
- 5 k) mir-24-1 comprising the sequence SEQ ID No. 11, or a sequence having at least 90% nucleotide identity with SEQ ID No. 11
- l) mir-24-2 comprising the sequence SEQ ID No. 12, or a sequence having at least 90% nucleotide identity with SEQ ID No. 12
- 10 m) mir-483 comprising the sequence SEQ ID No. 13, or a sequence having at least 90% nucleotide identity with SEQ ID No. 13
- n) mir-34a comprising the sequence SEQ ID No. 14, or a sequence having at least 90% nucleotide identity with SEQ ID No. 14
- 15 o) mir-34b comprising the sequence SEQ ID No. 15, or a sequence having at least 90% nucleotide identity with SEQ ID No. 15
- p) mir-34c comprising the sequence SEQ ID No. 16, or a sequence having at least 90% nucleotide identity with SEQ ID No. 16
- q) mir-20a comprising the sequence SEQ ID No. 17, or a sequence having at least 90% nucleotide identity with SEQ ID No. 17
- 20 r) mir-20b comprising the sequence SEQ ID No. 18, or a sequence having at least 90% nucleotide identity with SEQ ID No. 18
- s) mir-15a comprising the sequence SEQ ID No. 19, or a sequence having at least 90% nucleotide identity with SEQ ID No. 19, and
- t) mir-15b comprising the sequence SEQ ID No. 20, or a sequence having at least 90% nucleotide identity with SEQ ID No. 20.

25

- 5. The composition of claims 1 to 4, wherein the said inhibitor of a miRNA is an oligonucleotide of 8-49 nucleotides in length having a sequence targeted to the said miRNA, or a precursor thereof.

30

- 6. The composition of claim 5, wherein the said oligonucleotide is an antisense oligonucleotide that is at least partially complementary to the sequence of the target miRNA, or a precursor thereof.

7. The composition of claim 6, wherein said antisense oligonucleotide is selected from the group consisting of a ribonucleotide, a deoxyribonucleotide, a small RNA, an antagonmir, a LNA, a CDNA, a PNA, a morpholino oligonucleotide or a combination thereof.

5

8. The composition of claim 6, wherein said oligonucleotide consists of an antagonmir.

9. The composition of claim 8, wherein said antagonmir comprises a nucleotide sequence comprising at least 16 contiguous nucleotides complementary to the nucleotides of a sequence selected from the group consisting of SEQ ID No. 1 to 58.

10. The composition of claim 9, wherein said antagonmir comprises the sequence SEQ ID No. 59 or 60 and modifications excluding base substitutions thereof, and 15 fragments consisting of subsequences of SEQ ID NO: 59 or 60 of at least 8 contiguous nucleotides thereof.

11. The composition of claims 1 to 10, wherein said microspheres are presenting a diameter which does not exceed 25 μm .

20

12. The composition of claims 1 to 10, wherein at least 50% of said microspheres are presenting a diameter comprised between 5 and 20 μm , preferentially between 5 and 15 μm .

25

13. The composition of claims 1 to 12, wherein the microspheres are incorporating from 1% to 15 % w/w of inhibitor.

14. The composition of claims 1 to 12, wherein the microspheres are incorporating from 1% to 10 % w/w of inhibitor.

30

15. The composition of claims 1 to 14, wherein said microspheres are made of a polymer consisting of poly-d,l-lactide (PLA), the said polymer being optionally blended with one or more other polymers.

16. The composition of claims 1 to 14, wherein said microspheres are made of a copolymer consisting of poly-d,l-lactide-co-glycolide (PLGA), the said polymer being optionally blended with one or more other polymers.

5 17. The composition of claims 1 to 14, wherein said microspheres are made of a blend of polymers consisting of poly-d,l-lactide-co-glycolide (PLGA) and poly-d,l-lactide (PLA).

10 18. The composition of claim 16 or 17, wherein the ratio of lactide:glycolide in the PLGA polymer is comprised between 50:50 to 95:5 molar ratio.

19. The composition of claims 16 to 18, wherein the inherent viscosity of the polymer is comprised between 0.1 and 0.70 dl/g.

15 20. The composition of any one of the preceding claims for use in the treatment of the myocardial infarction.

21. The composition of claim 20 wherein said myocardial infarction consists of the acute myocardial infarction.

20 22. A method of reversing or preventing ventricular remodelling in a subject in need thereof comprising administering to said subject an effective amount of a composition according to one of the claims 1 to 19.

25 23. The method of claim 22, wherein said administration consists of an administration by intracoronary route.

24. A population of biodegradable and biocompatible microspheres for use in the treatment or prevention of myocardial infarction, wherein said microspheres:

30 - have an average diameter comprised between 5 and 15 μm ;

- are made of poly-d,l-lactide-co-glycolide (PLGA) ; poly-d,l-lactide (PLA) or a blend thereof;

- are incorporating from 1% to 15% w/w of a therapeutic agent capable of preventing ventricular remodelling,

wherein said therapeutic agent consists of an inhibitor of a miRNA selected from the group consisting of miR-92 (including miR-92a-1, miR-92a-2 and miR-92b), miR-17, miR-503, miR-16 (including miR-16-1 and miR-16-2), miR-374 (including miR-374a, miR-374b and miR-374c), miR-24 (including miR-24-1 and miR-24-2), miR-483, miR-34 5 (including miR-34a, miR-34b and miR-34c), miR-20 (including miR-20a and miR-20b), miR-15 (including miR-15a and miR-15b) and more preferentially miR-92a, or a precursor thereof.

25. The microspheres of claim 24, wherein said inhibitor is an antagonmir.

10

26. A kit comprising at least i) a composition according to claim 1 to 19 and/or microspheres according to claims 24 or 25 and ii) a syringe or vial or ampoule in which the composition is disposed.

15

27. The kit of claim 26, further comprising a solvent disposed in a solvent container.




Figure 1




Figure 2

Albumin Microspheres administration : 15 mg x 6 + 30 mg x 1 + SF 10 ml + SF 20 ml + Isch 5 min / Rep 10 min




Figure 3




Figure 4





Figure 5

A**B****Figure 6**








Figure 7

**Figure 8****Figure 9**

**Figure 10**

Antagomir 92a-treatment

**Figure 11**




Figure 12